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Abstract: Bacteria-Macrophage interactions in the Pathogenesis of 
Crohn’s Disease 
Paul Kevin Flanagan 
Crohn’s disease (CD) is associated with defective innate immunity, including impaired 
neutrophil chemotaxis, and mucosal invasion by bacteria, particularly E. coli that replicate 
inside macrophage phagolysosomes.  
In this thesis several hypotheses were tested: 
(i) that CD macrophages might be defective at killing and or responding to Gram-
negative bacteria, particularly E. coli;  
(ii) that killing of phagocytosed bacteria within macrophages might be enhanced 
by drugs such as hydroxychloroquine (HCQ) (previously shown to raise 
intravacuolar pH), and vitamin D (previously shown to enhance macrophage 
function). 
I assessed CD peripheral blood monocyte-derived macrophages (MDM) for their abilities to 
kill E. coli, with and without HCQ and vitamin D, and to generate neutrophil 
chemoattractants. 
MDM from patients with CD were similar to those from healthy controls (HC) in allowing 
replication of phagocytosed CD-derived E. coli: HM605 [CD N=10, mean fold replication in 
3h: 1.08, (95% confidence interval (CI) 0.39-1.78); HC N=9, 1.50, (95%CI 1.02-1.97); P=0.15] 
and also in generation of neutrophil chemoattractants in response to E. coli (mean fold 
chemotaxis relative to control: CD 2.55, 95%CI 2.31-2.80; HC 2.65, 95%CI 2.46-2.85, 
P=0.42). The only possible exception was reduced bacterial killing in macrophages from the 
relatively rare patients homozygous for ATG16L1 polymorphisms, reported previously and 
confirmed in the single example in this series. HCQ and 1,25 OH2-vitamin D3 both caused 
dose-dependent inhibition of intra-macrophage E .coli replication 3h post-infection, HCQ: 
73.9% inhibition (P<0.001) at 1μg/mL, accompanied by raised intra-phagosomal pH, and 
1,25OH2-Vitamin D3: 80.7% inhibition (P<0.05) at 80nM. HCQ had synergistic effects with 
doxycycline and ciprofloxacin on killing of phagocytosed E. coli. 
Thus: CD and HC macrophages generally perform similarly in allowing replication of 
phagocytosed E. coli and generating neutrophil chemoattractants. Replication of 
phagocytosed E. coli was substantially decreased by HCQ and vitamin D. These warrant 
further therapeutic trials in CD in combination with relevant antibiotics.  
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1 Introduction  
1.1 Inflammatory bowel disease 
1.1.1 Definition 
Inflammatory bowel disease (IBD) is a general term used to describe a chronic 
relapsing-remitting condition typified by inflammation of the gastrointestinal tract.  
It comprises two main clinical phenotypes, Crohn’s disease and ulcerative colitis 
(UC).  The two conditions share some common features but are commonly 
differentiated by disease location - Crohn’s disease can affect any part of the 
gastrointestinal tract; by disease behaviour - Crohn’s disease commonly causes 
stricturing and fistulation; and by histological features - Crohn’s disease causes 
transmural inflammation and classically leads to granuloma formation (Abraham 
2009). This thesis and the introduction herein is concerned primarily with Crohn’s 
disease. 
1.2 Crohn’s disease 
1.2.1 History of Crohn’s disease 
Historical descriptions of intestinal disorders can be found both in classical 
literature and again in the 19th century (Combe 1813), latterly reinterpreted as 
perhaps the first reports of inflammatory bowel disease, but it was not until the 
20th century that ulcerative colitis and Crohn’s disease were formally described.  In 
his paper “Chronic Interstitial Enteritis” Dalziel detailed nine cases of chronic 
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colonic and/or small bowel inflammation, now taken as one of the earliest modern 
descriptions of Crohn’s disease, bearing a striking similarity to the “pseudo-
tuberculous” chronic enteritis affecting cattle, Johne’s disease (Dalziel 1913).  
However it was not until the 1932 publication of a paper in JAMA that Crohn’s 
disease acquired its eponymous name and the different disease phenotypes, still 
recognisable to a modern physician, were accurately reported (Crohn 1932), 
although Crohn’s disease affecting only the colon was not widely accepted until 
1960 (Lockhart-Mummery 1960).  
 
1.2.2 Definition 
Crohn’s disease is a condition characterised by a range of common clinical, 
radiological, histological and endoscopic features as defined by Lennard-Jones 
(Lennard-Jones 1989), and affirmed by the European Crohn’s and Colitis 
Organisation (ECCO) (Van Assche 2010).   
 
1.2.3 Clinical features 
1.2.3.1 Symptoms 
Symptoms may vary dependent on disease location but commonly include 
diarrhoea (in around 90%), rectal bleeding (around 50%) (Lennard-Jones 1997), 
abdominal pain (70%) and weight loss (60%) (Stange 2006).  Up to 20% of patients 
will develop a perianal fistula at some point in their disease course and the overall 
lifetime risk for some form of penetrating disease is 20-40% (Nordgren 1992; 
Schwartz 2002). 
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Extra-gastrointestinal problems occur more commonly than in ulcerative colitis and 
are seen in around one third; typical manifestations include oral aphthous ulcers, 
uveitis, erythema nodosum, pyoderma gangrenosum, psoriasis, peripheral 
arthropathy, axial arthropathy and primary sclerosing cholangitis (PSC), the latter 
almost exclusively in those with colonic disease.  Extra-intestinal problems are 
multiple in 39% of affected patients and in 26% present before the diagnosis of IBD 
(Vavricka 2015). 
 
1.2.3.2 Histopathology 
Differentiation between Crohn’s disease and ulcerative colitis can be challenging 
and there is no single defining pathological feature of Crohn’s disease.  Crohn’s 
disease is strongly favoured by biopsies showing evidence of small bowel or patchy 
colonic disease, non-cryptolytic non-necrotic granulomas, segmental crypt 
distortion and an absence of mucin depletion (Feakins 2013).  In surgical specimens 
transmural inflammation, transmural lymphoid hyperplasia and submucosal nerve 
fibre hyperplasia are considered typical, whilst granulomas, fibrotic submucosal 
thickening and fissures are strongly supportive (Van Assche 2010). 
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1.2.3.3 Endoscopic features 
Colonoscopy remains one of the mainstays of investigation in Crohn’s disease, both 
for diagnosis and disease assessment.  Two main scoring systems are described for 
determining disease activity via colonoscopy, the Crohn’s disease Endoscopic Index 
of Severity (Mary 1989) and the Simple Endoscopic Score for Crohn’s Disease (SES-
CD) (Daperno 2004).  Both objectively quantify the severity of mucosal ulceration 
and any strictures present and both are prospectively validated but neither are 
widely used in routine clinical practice (Tontini 2014).   For post-operative disease 
assessment the Rutgeerts’ score, a simple measure of the number of ulcers and 
severity of inflammation at an ileo-colonic anastomosis (disease relapse is defined 
as a score of ≥2) is widely used and prospectively validated (Rutgeerts 1990). 
Small bowel disease may also be assessed and quantified using capsule endoscopy 
(for patients with non-stricturing disease- the capsule can be retained in narrowed 
segments of bowel and may lead to obstruction), where the observed mucosal 
changes can be classified into normal, mild or moderate-severe disease using the 
Lewis score, now shown to correlate with the need for treatment and 
hospitalisation (Dias de Castro 2015).  
 
1.2.3.4 Radiological findings 
A wide range of radiological modalities are now available for imaging Crohn’s 
disease including small bowel MRI, small bowel MR enteroclysis (MRI enhanced by 
the distension of the small bowel with a contrast medium instilled via a naso-gastric 
tube), CT scanning, barium studies (either a small bowel follow through or a small 
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bowel enteroclysis), white cell scanning and ultrasound.  Choice of modality is still 
determined in large part due to local availability (Hafeez 2011) and the need to limit 
radiation burden which can be excessive in up to 10% of patients (Chatu 2012).  For 
diagnosis MRI has a sensitivity and specificity of >90%, while CT has high specificity 
(>90%) but much lower sensitivity and contrast studies perform less well on both 
counts (Gatta 2012).   When assessing for complications of Crohn’s disease CT and 
MRI perform comparably but CT will often be used first line due to the speed and 
availability of scanning.  Ultrasound is reported to have sensitivity and specificity of 
>90% but it is highly operator dependent and availability of intestinal ultrasound is 
patchy in the UK (Gatta 2012).  
1.3 Classification 
Crohn’s disease is a heterogeneous condition in which there are groups of common 
phenotypes.  The Montreal classification (detailed in Table 1), a modification of the 
earlier Rome and Vienna classifications, is the currently accepted system for 
describing this variation in disease location and behaviour according to the 
observed clinical characteristics (Silverberg 2005).  Classification is not however a 
fixed entity and may evolve over time, most commonly in relation to disease 
behaviour (B) (changing in 45.9% of patients by 10years) and less frequently 
regarding location (L) (changing in 15.9% of patients by 10 years) (Louis 2001). 
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Age at Diagnosis (A) 
A1 ≤16 years 
A2 17-40 years 
A3 >40 years 
Location (L) 
L1 Terminal ileum 
L2 Colon 
L3 Ileocolon 
L4 Upper GI  (May also be added to L1-3 as a disease modifier) 
Behaviour (B) 
B1 Non-stricturing, non-penetrating 
B2 Stricturing 
B3 Penetrating 
p Perianal disease modifier which may be added to B1-3 
 
Table 1: Montreal classification of Crohn’s disease. Adapted from (Silverberg 2005)   
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1.4 Disease markers 
1.4.1 Serological markers 
1.4.1.1 Circulating antibodies 
Atypical peri-nuclear anti-neutrophil antibodies (pANCA) are more strongly 
associated with ulcerative colitis but around 20-30% of patients with Crohn’s 
disease are pANCA positive although its presence is strongly associated with colonic 
disease, with one study demonstrating that 100% of patients testing positive for 
pANCA had colonic involvement (50% ileocolonic, 50% isolated colonic) 
(Vasiliauskas 1996).  In UC pANCA positivity has been associated with resistant left 
sided colitis, early surgery and increased disease duration but no significant 
association with disease behaviour has been demonstrated in Crohn’s disease 
(Elkadri 2013). 
Anti-Saccharomyces cerevisiae antibody (ASCA) is detectable in up to 68% of 
patients with Crohn’s disease (Reese 2006), is more strongly associated with small 
bowel disease (Odds ratio (OR) 2.2) and positive IgG serology is associated with 
stricturing/penetrating disease (OR 3.01) (Ryan 2013). ASCA antibodies are directed 
against microbial cell wall mannan, an epitope also expressed by Candida albicans 
and Mycobacterium avium subsp paratuberculosis (MAP) (Mpofu 2007).  A similar 
mannan is also known to be the receptor for bacterial FimH on its receptor 
(Uroplakin) in bladder epithelial cells and it is conceivable that a similar structure 
may also act as receptor for FimH on glycoprotein 2 (GP2), its receptor on the 
luminal surface of microfold (M) cells overlying Peyer’s patches (Hase 2009; 
Wellens 2008). 
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Antibodies to Escherichia coli outer membrane porin protein C (anti-OmpC) are 
found in 37-46% of Crohn’s disease patients and are associated with fistulating 
disease, disease progression and need for surgery (Arnott 2004; Mow 2004).   
Pancreatic autoantibodies (PAB), the autoantigen for which is the major zymogen 
granule membrane glycoprotein 2 (GP2) (Roggenbuck 2009), are found significantly 
more frequently in Crohn’s disease patients (around 1/3
rd) than in unaffected family 
members or patients with ulcerative colitis (both around 23%) (Joossens 2004).  No 
consistent associations with disease phenotype or behaviour have been shown, 
with data conflicting (Desplat-Jego 2007; Lakatos 2009), but their presence overlaps 
with the presence of ASCA and has been linked to a possible microbial pathogenic 
mechanism (Lakatos 2009).  It is not yet clear if PAB positivity represents a primary 
or secondary phenomenon but it may arise as a consequence of bacterial mediated 
small bowel inflammation; GP2 is found on the apical membrane surface of small 
intestinal Microfold (M) cells, binds to the FimH protein component of bacterial 
outer membrane type 1 pili, and mediates translocation of bacteria across M-calls 
(Hase 2009) – it follows, but remains unproven, that PAB may arise as a 
consequence of bacterial induced inflammation (Pavlidis 2012) 
Antibodies to Pseudomonas fluorescens associated sequence I2 (anti-I2) are seen in 
50-54% of patients (Landers 2002), are associated with stricturing disease, disease 
progression and the need for surgery (Prideaux 2012).   
Antibodies to the microbial cell wall carbohydrates mannobioside (AMCA), 
laminaribioside (ALCA) and chitobioside (ACCA), collectively referred to as anti-
glycan antibodies, are positive in around 40% of patients and high titres are 
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associated with a more aggressive disease course and an increased likelihood or 
having steroid dependent disease (Paul 2015).  Similarly, antibodies to the Flagellin, 
CBir1, are detectable in 50-55% of patients and are associated with small bowel, 
stenosing and penetrating disease (Targan 2005). 
Studies conducted on the stored sera of military personnel who later develop 
Crohn’s disease have demonstrated the presence of these antibodies, including 
ASCA, anti-flagellin antibodies and anti-OmpC, in up to two thirds of patients with a 
median interval of antibody formation to disease development of between 3 and 6 
years (Choung 2016; Israeli 2005).  Furthermore, a panel of serological markers may 
also identify patients from a normal population at higher risk of developing IBD (van 
Schaik 2013).   
Whilst no single serological marker has sufficient sensitivity or specificity to be used 
for diagnostic purposes (Prideaux 2012), combining assays can differentiate Crohn’s 
disease and UC with positive predictive values of 92.5-96% (Quinton 1998).  Despite 
this apparently impressive figure, their main current utility is as a diagnostic aid in 
difficult cases, but an emerging role in predicting disease behaviour (Ryan 2013), 
particularly when combined with genetic tests, hints at a more clinically useful 
future use (Lichtenstein 2011; Plevy 2013).   
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1.4.1.2 Biological markers 
C reactive protein (CRP) is a non-specific marker of inflammation commonly used to 
help differentiate inflammatory and non-inflammatory causes of gastrointestinal 
symptoms, as well as to monitor disease activity in patients with established 
inflammatory bowel disease where an elevated level correlates with endoscopic 
evidence of inflammation (Mosli 2015).  However it is not sensitive and normal 
levels are seen in 10-25% of patients with active disease, most commonly in 
patients with isolated small bowel disease (Florin 2006; Henriksen 2008; Karoui 
2007).  Further, adiposity may lead to a false positive result due the role of 
mesenteric fat in producing CRP (Peyrin-Biroulet 2012).   Despite these limitations it 
remains a useful tool for disease assessment and may be used to predict treatment 
efficacy as low levels are associated with lower response rates to biologics (Jurgens 
2011). 
Calprotectin is a neutrophil protein released from inflamed tissue and detectable in 
the faeces of patients.  It is supported by the National Institute for Health and Care 
Excellence (NICE 2013) to be used as a screening test to differentiate irritable bowel 
syndrome (IBS) from inflammatory bowel disease where it has a pooled sensitivity 
of 93% and specificity of 96% (van Rheenen 2010).  It is a well established test for 
colonic and ileocolonic disease. Early studies raised questions about its reliability in 
isolated ileal disease (Sipponen 2008) but more recent studies have shown good 
correlation between calprotectin levels and small bowel inflammation as 
determined by MRI or surgical resection (Cerrillo 2015) although sensitivity is lower 
than in colonic disease (Stawczyk-Eder 2015).  Calprotectin can also be used to 
predict the risk of relapse in patients with well controlled disease.  In the STORI 
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trial, elevated calprotectin (>300μg/g) predicted relapse following withdrawal of 
infliximab, a finding confirmed in a recent meta-analysis (Louis 2012; Mao 2012) 
and, in a prospective trial, a level of <240μg/g in quiescent patients had a 96.8% 
negative predictive value for the risk of relapse (Naismith 2014).  In post-surgical 
patients levels of <100μg/g have been shown to have a 91% negative predictive 
value for endoscopically detectable disease recurrence at 6 months (Wright 2015).  
Finally, much interest surrounds its use a as a surrogate for endoscopic assessment 
of mucosal healing, with one study showing a 94.1% sensitivity to do so with levels 
of <250μg/g (D'Haens 2012) and another reporting a 79% sensitivity with levels of 
<121μg/g (Guidi 2014) but a more recent study has reported that any level above 
50μg/g is predictive of endoscopic disease activity (Falvey 2015).  The use of 
calprotectin in this area requires further studies.  The neutrophil protein lactoferrin 
has comparable diagnostic utility and performance but is less stable at room 
temperature and consequently its use has not translated into widespread clinical 
use (Mosli 2015).  
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1.4.1.3 Serological overlap between colonic Crohn’s disease and ulcerative colitis 
Colonic Crohn’s disease (Montreal L2) is currently considered a separate entity to 
ulcerative colitis, but recent data suggests there is significant overlap, raising the 
possibility they may be spectrums of the same disease process.  Both are more 
often negative for ASCA , commonly positive for pANCA and additionally both are 
negative for the nucleotide-binding oligomerization domain-containing protein 2 
(NOD2) gene association and strongly associated with the HLA DRB1*0103 
haplotype (Hugot 2001; Reese 2006; Silverberg 2003).  A recent very large 
international multicentre genotype-phenotype association study has shown that 
isolated colonic Crohn’s disease is genetically separate from Crohn’s disease with 
ileal involvement, lying approximately midway between the latter and ulcerative 
colitis (Cleynen 2016). 
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1.5 Epidemiology 
1.5.1 Incidence and Prevalence 
In the UK, the incidence of Crohn’s disease has risen progressively over the last 75 
years and varies between 7 and 9.56 per 100,000 population per year, with a 
prevalence of around 150 per 100,000 (Gunesh 2008; Rubin 2000; Steed 2010).  The 
UK has some of the highest rates recorded and it should be noted that significant 
world wide variation in incidence and prevalence is seen (Burisch 2013).   Within 
this variation two notable patterns have emerged; a north-south gradient, with the 
highest rates seen in northern latitudes, and an east-west European gradient, with 
populations of western European countries demonstrating a far higher disease 
burden than those in East despite similar population characteristics (Burisch 2014a; 
Shivananda 1996).  It is not however, contrary to the historical view, a condition of 
Europe and North America, as there has been a clear emergence of the disease in 
Asia-Pacific where studies over the last two decades have demonstrated a rapidly 
rising incidence (Ouyang 2005; Yang 2008).  This rise in Asia may in part be due to 
increasing westernisation, a view that is given further credence by the observation 
that patients who emigrate from low to high prevalence countries have an 
increased rate of IBD relative to controls (Ahuja 2010; Barreiro-de Acosta 2011).   
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1.5.2 Age 
Crohn’s disease has a bimodal pattern of incident age with the majority of patients 
presenting between the ages of 20 and 30years (with an average age of onset 5-10 
years earlier than ulcerative colitis) but up to 15%  occurring after 65 years 
(Ananthakrishnan 2009; Cosnes 2011; Duricova 2014).  The latter tend more 
commonly to have colonic disease and it is possible that some of these represent 
cases of segmental colitis associated with diverticular disease (SCAD) that has a 
similar histology (Gisbert 2014).  Some uncertainty exists over the proportion of 
patients presenting in childhood, largely due to variations in age cut offs for 
paediatric services, but it is thought between 7 and 25% present in childhood or 
adolescence (Cosnes 2011; Henderson 2012).   
 
1.5.3 Sex 
For adult Crohn’s disease in North America  and Northern and Western Europe 
there is a slight predominance in females, whereas the reverse holds true in Asia, 
and females more commonly develop extraintestinal manifestations of their 
disease (Molodecky 2012; Vavricka 2015).  In the UK females are affected 1.3-1.6 
more frequently than males (Gunesh 2008; Rubin 2000).  In patients with a family 
history of Crohn’s disease this female preponderance hold true  (ratio 1.5:1) and 
additionally the index case is more commonly the mother, suggesting there may be 
sex-specific mechanisms  affecting the risk of progeny developing Crohn’s disease 
(Zelinkova 2012).  The picture in paediatric disease is different however where a 
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clear male predominance is seen, a pattern which persists until after adolescence 
(Sagiv-Friedgut 2010). 
 
1.5.4 Ethnicity 
In addition to the world wide variations in incidence and prevalence, certain ethnic 
groups within national populations are at elevated risk.  Jewish people have an 
increased risk of Crohn’s disease relative to non-Jewish white people (relative risk 
5.4-7.7) (Mayberry 1986), a risk that is higher in Ashkenazi Jews relative to 
Sephardic Jews (Roth 1989) and the life time risk of a first degree relative of a 
Jewish patient with Crohn’s disease also developing the disease is 7.8%, compared 
to 5.2% in non-Jewish families (Yang 1993).  The observed risk in Jewish patients, at 
least in part, has a genetic basis (Kenny 2012), but other migrant populations are 
also at increased risk relative to Caucasian populations, perhaps due to 
environmental factors -  patients with Indian sub-continent ancestry living in the UK 
and the USA both have an elevated incidence of Crohn’s disease (Bhopal 2014; 
Malhotra 2015).  Conversely a nationwide study of disease prevalence in the USA 
has clearly shown Crohn’s disease to be less common in non-white sub-populations 
(Nguyen 2014) and further, contrary to previous studies suggesting more severe 
disease in African-American patients, disease behaviour appears similar to white 
American patients (Mahid 2008). 
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1.5.5 Health/social class 
Given the higher rates of disease in the western world, it might be expected that 
higher economic standing may also increase risk.  In a retrospective study of 
paediatric Crohn’s disease in Scotland an association was seen with higher social 
class (Armitage 2004)but in a prospective French study this was not shown to be 
the case, nor was deprivation associated with poorer disease outcomes, perhaps 
due to the high quality French healthcare system (Nahon 2009).  
1.6 Disease risk factors 
1.6.1 Genetics 
Direct evidence for a genetic component to Crohn’s disease pathogenesis came in 
the 1990s with the genome wide search of groups of disease affected families and 
subsequent identification of a disease susceptibility locus on chromosome 16 
(Hugot 1996).  In a seminal paper this was then shown to be due to two missense 
variants and a frameshift variant in the NOD2/CARD15 (nucleotide- binding 
oligomerization domain-containing 2/ caspase recruitment domain-containing 
protein 15) gene (Hugot 2001) expressed in paneth cells, macrophages and 
epithelial cells and associated with ileal Crohn’s disease (Ahmad 2002). 
Genome wide association studies (GWAS) have now identified 206 distinct single 
nucleotide polymorphisms (SNP) associated with IBD disease susceptibility, mostly 
shared across diverse ethnic groups although with some geographical variation 
(Ellinghaus 2016; Liu 2015).  Where present, genetic risk is shared with other 
immune mediated diseases including psoriasis, ankylosing spondylitis, type 1 
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diabetes mellitus and leprosy (Barrett 2008; Franke 2010; Jostins 2012; Zhang 
2009), and recent publications have suggested the observed genetic overlap may in 
fact explain some of the variation in disease phenotype seen in IBD.  Specifically it 
has been suggested that patients with primary sclerosing cholangitis (PSC) or 
extraintestinal manifestations of IBD may represent a sub-population genetically 
distinct from unaffected IBD patients and that these complications may arise as a 
consequence of polymorphisms shared with other auto-immune conditions 
(Ellinghaus 2016). 
Arguably, the most significant impact of GWAS studies has been to implicate 
specific immune and cellular pathways leading to a greater understanding of 
underlying disease mechanisms.  For Crohn’s disease these can be grouped broadly 
into two key categories:  innate immunity (autophagy, microbial recognition – 
NOD2, ATG16L1, IRGM) and acquired immune response regulation (lL23 signalling 
and Th17 cells – IL23R) (Jostins 2012).  Significantly there is overlap with infectious 
diseases, specifically a shared risk with Mycobacterial disease (NOD2, IL23R, 
TNTSF15) (Jostins 2012; Zhang 2009).  Mucosal barrier function, important in UC, 
does not appear so relevant for Crohn’s disease (Lees 2011). 
Individually the majority of identified risk loci have small odds ratios (Jostins 2012) 
but composite models demonstrate a cumulative effect with an increased genetic 
risk of disease for both affected patients and their first degree relatives in 
comparison to healthy controls (Kevans 2016). However there is marked overlap – 
many patients have a genetic risk comparable to the normal population and 14% of 
healthy controls without any family history of disease have a significant genetic risk 
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for Crohn’s disease.   These findings, comparable to an earlier study in which 70 of 
the then known 71 Crohn’s disease specific risk alleles were typed,  suggest that 
disease development is due to genetic risk in only a minority of patients (Hedin 
2014). 
Findings from family and twin studies also suggest that genetics only play a partial 
role in disease pathogenesis.  Only 6-12% of Crohn’s disease patients have a family 
history of the disease (Moller 2015), <1% of the offspring of affected patients 
develop IBD (Orholm 1999), and, in the latest analysis, the Swedish twin registry has 
shown concordance in monozygotic twins to be as low as 27% (Halfvarson 2011).   
Indeed only 13.6% of disease variance is explained by the currently known disease 
associated polymorphisms and it is possible environmental factors alone might be 
sufficient to trigger disease, perhaps by inducing alterations in gene expression or 
innate immune function (Jostins 2012).  Epigenetic factors, such as alterations in 
DNA methylation, histone proteins and chromatin, are one such possible 
mechanism  through which environmental factors may exert functional changes 
which ultimately lead to disease development (Ventham 2013).  Intriguingly DNA 
hyper- and hypo-methylation may be observed in both peripheral immune cells and 
intestinal mucosa, and this has been shown to alter mRNA production suggesting a 
functional role (McDermott 2016). 
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1.6.2 Environmental factors 
1.6.2.1 Diet 
Epidemiological and interventional studies as well as animal models and in vitro 
assays all provide evidence for a dietary influence in the development of Crohn’s 
disease.  These effects may begin at an early age.  A systematic review of the 
impact of breastfeeding demonstrates a reduced risk of IBD seen in breast fed 
infants (OR 0.69) (Barclay 2009).  Effects may also be seen later in life and it has 
been hypothesized that the observed northern and western gradients in IBD 
prevalence, and the emergence of IBD in traditionally low prevalent counties, relate 
in part to the adoption of a westernised diet.  Epidemiological studies of migrant 
populations support this assertion, which is given further credence by the observed 
associated between disease incidence and components of a western diet, 
specifically emulsifiers and refined sugars (Lee 2015; Richman 2013; Roberts 2013).  
It therefore follows that dietary manipulation should influence disease severity.   
This hypothesis holds true both in animal models (where high fat and iron worsen 
disease but certain amino acids, vitamin D and several components of plant based 
feeds temper the inflammatory response) and in human trials where exclusive 
enteral nutrition induces remission in patients with active Crohn’s disease (Lee 
2015; Zachos 2007). 
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1.6.2.2 Smoking 
Both current (OR 1.65-2.47) and former smokers (OR 1.33-2.51) have an elevated 
risk of Crohn’s disease, the risk in the latter persisting for 5-10 years after smoking 
cessation (Calkins 1989; Tobin 1987).  Early studies reported rates of smoking 
amongst patients with Crohn’s disease to be as high as 50% but this is falling 
(perhaps due to the effects of taxation and public health policy) and more recent 
studies report rates of 19.2-33.2% (Lindberg 1988; Lunney 2015; Severs 2016).  In 
addition to their elevated disease risk, smokers also run a more severe disease 
course with higher rates of relapse, a greater need for first time and re-do surgery, 
higher rates of penetrating disease and a greater prevalence of extra-intestinal 
disease manifestations (Severs 2016; To 2016).  Light smokers have a risk equivalent 
to heavy smokers suggesting this is an all or nothing phenomenon, rather than a 
dose-dependent effect (Seksik 2009).  However, smoking cessation reverses risk 
and patients who stop have disease flare rates comparable to non-smokers and 
reduced need for escalation of medical therapy (Cosnes 2001; Johnson 2005).   
 
1.6.2.3 Oral Contraception 
Following on from earlier smaller studies a large meta-analysis of 14 trials, 
containing in excess of 75,000 women, demonstrated a 1.46 pooled relative risk 
(95% confidence interval 1.26-1.70) for developing Crohn’s disease in current users 
of the oral contraceptive pill (OCP).  Risk increases with time exposed to the OCP 
(Cornish 2008) . 
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1.6.2.4 Vitamin D 
Much recent interest has focussed on the role of vitamin D, in part due the high 
rates of disease in northern latitudes.  Low vitamin D levels are common, are 
associated with active disease, an increased risk of surgery and hospitalisation, and 
low predicted levels are associated with an increased risk of developing disease 
(Ananthakrishnan 2013a; Ananthakrishnan 2012; Jorgensen 2013; Suibhne 2012).  A 
therapeutic trial of vitamin D supplementation to prevent relapse showed a trend 
toward benefit but just failed to reach statistical significance (Jorgensen 2010). 
 
1.6.2.5 Westernisation and diet 
As discussed earlier, epidemiological studies inform us of a western predominance 
both in terms of Crohn’s incidence and prevalence.  The ECCO population-based 
inception cohort study, ECCO-EpiCom, report a two-fold increase in Crohn’s disease 
incidence in western Europe relative to the east (Burisch 2014a).  This difference 
could not be accounted for by differences in smoking, contraception use or family 
history and, paradoxically, other putative  environmental risk factors appeared 
more prevalent in eastern Europe (high sugar intake, low fibre intake, low fruit and 
vegetable consumption, low rates of childhood infections) although the study was 
limited by problems with accurate dietary information (Burisch 2014b).  Data from 
Asia-Pacific countries have more strongly suggested an effect from westernised 
lifestyles with a western diet before the age of 20 and a sedentary lifestyle both 
associated with an increased risk of Crohn’s disease in Asian patients (Ng 2015).  
Supporting the Asia-Pacific findings are the results from the USA Nurses’ Health 
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Study in which a dietary intake of fruit fibre in the highest quintile led to a 40% 
reduction in the risk of developing Crohn’s disease (Ananthakrishnan 2013b).  
 
1.6.2.6 Hygiene 
Many studies have identified increased rates of immune mediated diseases in 
countries with high per-capita incomes, a phenomenon correlated with the falling 
incidence of infectious diseases seen in resource rich locations.  This has led to the 
hygiene theory of disease pathogenesis in which it is proposed that naturally 
occurring exposure to microbes in early life leads to alterations in T helper cell 
activity, perhaps via changes in regulatory T cell function  and circulating cytokines, 
and thereby protects against immune related disease (Bach 2002). Population 
based studies have given credence to this theory with a striking increase in the risk 
of Crohn’s disease following childhood antibiotic use, a risk which increases with 
each subsequent course and is highest in the 3 months following treatment.  Data 
however have been conflicting with some studies reporting a protective effect from 
infection, others failing to show a clear correlation between hygiene and the risk of 
Crohn’s disease and studies from Asia and Italy failing to demonstrate any 
correlation with childhood antibiotic use and the risk of Crohn’s disease (Castiglione 
2012; Chu 2013; Ng 2015).  
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1.6.2.7 Occupation 
In a retrospective study of the U.S. national occupational mortality database, 
patients with an established diagnosis of IBD were shown to have higher mortality 
rates in white collar industries relative to manual workers, when assessed using a 
proportional mortality ratio model (in which observed deaths are compared to 
expected standardised mortality rates).  These findings have been consistent across 
three studies by the same authors covering a 22 year span, and have suggested a 
role for occupational environmental factors in disease associated mortality 
(Sonnenberg 2012).  However the effect of occupation on the need for 
hospitalisation with Crohn’s disease was less consistent and of a lower magnitude 
when studied using Swedish national databases, suggesting the effect of occupation 
is weak at most (Li 2009). 
 
1.6.2.8 Appendicectomy 
The apparent protective effect of appendicectomy in ulcerative colitis and some 
studies in Crohn’s disease have raised the possibility that appendicectomy may be a 
risk factor for Crohn’s disease.  However a Scandinavian cohort study of more than 
700,000 patients has failed to show a major effect, with only a modest increase in 
Crohn’s disease seen post surgery, a finding most pronounced in the first six 
months post-appendicectomy.  Crohn’s disease is well recognised to mimic the 
signs and symptoms of appendicitis and the authors conclude that any association  
is probably an artefact brought about by diagnosis bias (Kaplan 2007). 
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1.6.2.9 Psychological stress 
In a large meta-analysis looking at the effect of work-related stress on the risk of 
developing IBD, no association was seen for either UC or Crohn’s disease (Heikkila 
2014).  However prospective studies have shown stress to be associated with the 
risk of Crohn’s disease flares, probably via a number of different mechanisms 
including effects on the hypothalamus, gut microbiota and mast cells (Mardini 
2004; Mawdsley 2005). 
 
1.6.2.10 Environmental factors precipitating disease flares 
GI infection may precipitate relapse in around 10% of patients with Clostridium 
difficile the cause in around half of these cases (Mylonaki 2004).  Seropositivity for  
cytomegalovirus (CMV) occurs commonly in patients with Crohn’s disease but its 
relevance and role in disease is much debated – a recent study of 249 patients did 
not find an association with disease objective markers of disease activity and 
concluded that CMV is likely to be a bystander (do Carmo 2014). 
Use of non-steroidal anti-inflammatory drugs (NSAIDs) is commonly avoided due to 
a perceived risk of inducing disease flare although evidence for this is weak and a 
systematic review demonstrated only a small effect.  The same study suggested 
paracetamol, commonly used as an alternative, may also carry some risk (Forrest 
2004).   
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1.7 Disease associations 
1.7.1 Orofacial granulomatosis 
Orofacial granulomatosis (OFG) is an umbrella term to describe a chronic 
granulomatous condition affecting the oral cavity and/or the face and encompasses 
a range of conditions, namely; isolated oral Crohn’s disease, oral sarcoidosis, 
cheilitis granulomatosa and Melkersson-Rosenthal syndrome (Challacombe 1997).  
It’s presence in childhood has a stronger association with intestinal Crohn’s disease 
(40% of patients) whereas in adult onset disease only a quarter of patients are 
similarly affected (Lazzerini 2014).  In around half of patients a diagnosis of OFG 
pre-dates the later development of Crohn’s disease (Campbell 2011; Gale 2016). 
 
1.7.2 Rheumatological disease 
Around one third of patients with Crohn’s disease develop rheumatological 
symptoms falling into one of three main groups; type 1 peripheral arthropathy in 
which <5 joints are affected and which classically mirrors intestinal disease activity, 
type 2 peripheral arthropathy in which >5 joints are affected and which is generally 
independent of IBD activity, and axial disease which may manifest as inflammatory 
back pain, sacroiliitis or ankylosing spondylitis (AS) (Ott 2013). 
HLA-B27 seropositivity in Crohn’s disease is slightly more common than the general 
population and is strongly associated with the development of sacroiliitis although 
interestingly appears to be less important in disease associated ankylosing 
spondylitis than in idiopathic AS (Orchard 2009).  Of patients with idiopathic AS less 
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than 10% will develop Crohn’s disease although nearly three quarters have 
subclinical intestinal inflammation (Reveille 2012). 
There may be shared pathological mechanisms and indeed Crohn’s disease shares 
genetic factors with psoriatic arthropathy and ankylosing spondylitis, including 
polymorphisms in IL-12, IL-23R and the NFκB pathway (Reveille 2012).  Moreover 
similar patterns of T cell upregulation and cytokine production may be observed in 
Crohn’s disease and the spondyloarthropathies leading to the hypothesis that the 
rheumatological disease arises as a consequence of primed immune cells circulating 
to the joint space from the gut (Fantini 2009). 
 
1.7.3 Chronic granulomatous disease and other rare single gene disorders  
Chronic granulomatous disease is a rare disorder arising from genetic mutations in 
the NADPH oxidase complex and is x-linked in 65% of cases.  This leads to an 
immunodeficiency state as a consequence of impaired neutrophil function which 
then results in recurrent infection.  Many will develop GI symptoms and nearly half 
develop a Crohn’s disease like illness (Marks 2009).   
Very early onset IBD, infantile IBD and neonatal IBD (i.e. those variants of IBD 
presenting under the age of 6) are commonly monogenic and frequently due to 
defects in immune function including impaired phagocyte function, T-cell defects, 
B-cell defects and failures of immune regulation.  These IBD variants are typified by 
a predominance of colonic disease, higher rates of complex perianal disease and 
relative resistance to conventional treatments (Uhlig 2014).   
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1.8 Natural history 
1.8.1 Effect of age on disease progression 
The age of presentation is an important factor in disease behaviour.  Paediatric 
Crohn’s disease more commonly affects the colon and the proximal GI tract 
(perhaps a consequence of higher pick up rates due to routine use of upper GI 
endoscopy in these patients) and tends to run a more aggressive course (Duricova 
2014).  In contrast, elderly patients (over 65 years) more commonly have isolated 
colonic disease,  are less likely to extend their disease to other locations after 
diagnosis,  less frequently suffer extraintestinal manifestations of their disease and 
are less likely to have complicated disease (Charpentier 2014).  Despite this it 
should be noted that elderly patients requiring inpatient care for their disease have 
higher admission-related adjusted mortality rates despite lower rates of surgery, 
fistulating disease, perianal disease and obstruction (Ananthakrishnan 2009). 
 
1.8.2 The role of genetics in predicting disease behaviour and treatment 
response 
NOD2 variants have long been associated with a greater risk of complicated disease 
and more recent models now suggest risk may be cumulative with additional gene 
variants conferring a progressively higher risk of complications (Gerich 2014).  More 
complex models using a combination of genetics, immune cell gene expression and 
circulating serological markers show some early promise but have yet to be 
prospectively validated in a real world population.  
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In an emerging field it seems likely genetic factors will have an increasing role in 
predicting the risk of adverse reactions to treatments for IBD.  Patients with the 
HLA-DQA1*02:01–HLA-DRB1*07:01 haplotype have a significantly elevated risk of 
thiopurine induced pancreatitis (Heap 2014) and HLA-DRB1*03:01 is associated 
with the risk of 5-aminosalicylate induced nephropathy (Heap 2016).  
Predicting treatment response is less certain but inconsistent data suggests a 
weaker response to tumour necrosis factor α (TNFα) antagonists in patients with a 
NOD2 variant and an enhanced response in patients with variants of the Fas ligand 
(Vermeire 2010b). Glucocorticoid resistance is associated with genetic variation in 
steroid receptors (NR3C1 gene), altered intracellular drug concentration (MDR1 
gene) and possibly genetically programmed over-production of pro-inflammatory 
cytokines (Gabryel 2016). 
 
1.8.3 Natural history of disease phenotypes 
Disease behaviour changes over time in the majority of patients although disease 
location generally remains fixed (Cleynen 2016; Cosnes 2002; Louis 2001).  Overall 
penetrating complications are commoner than stricturing, particularly in younger 
patients and those with perianal disease, with the latter most common in patients 
with small bowel disease and an absence of perianal involvement (Cosnes 2002).  At 
diagnosis 70-80% of patients have non-stricturing non-penetrating disease, with a 
22% risk of progression to either stricturing or penetrating disease by 1 year, 33-
43% by 5 years and 50% by 20 years (Cleynen 2016; Thia 2010).  
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1.8.4 Effect of treatment on disease progression 
Longitudinal studies, as might be expected, have shown increasing use of 
immunosuppressants and biological drugs over time, and also show an overall 
reduction in the need for surgery at 1 year, 5 years and 9 years after diagnosis, with 
a meta-analysis showing thiopurines to be associated with a lower risk of surgery, 
although this apparent treatment effect has not been consistent across all studies 
(Chatu 2014; Ramadas 2010; Rungoe 2014). 
It is conceivable this finding arises as a consequence of poorly defined treatment 
endpoints, and separate data shows patients who achieve mucosal healing 
(achievable with immunosuppressants and biologics) have reduced need for 
surgery, hospitalisation and steroids (Neurath 2012).  This, and lessons learnt from 
rheumatoid arthritis, has led to the concept of “treat to target” in which medical 
therapy is optimising to achieve hard end points (mucosal healing, normalisation of 
biochemical tests)  with the aim of controlling active disease and preventing long 
term complications (Bouguen 2015).  Whilst logical this approach lacks evidence 
from prospective trials and efficacy remains unproven. 
 
1.8.5 Prognostic factors 
Factors associated with an increased risk of long term disease complications are:  
peri-anal disease, steroid use at diagnosis, age under 40 at diagnosis, upper GI 
involvement, smoking, extensive small bowel disease, ileal involvement and 
stricturing or penetrating disease (Thia 2010).  
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1.9 Treatment 
1.9.1 5-aminosalicylates 
5-aminosalicylates (5ASAs) target the epithelial cell and are efficacious in UC but 
Cochrane reviews showed no benefit for the induction or maintenance of remission 
in Crohn’s disease (Akobeng 2005; Lim 2010) with a subsequent meta-analysis 
finding similar results (Ford 2011b) although there may be some benefit in 
preventing post-operative relapse (Ford 2011c). 
 
1.9.2 Steroids 
Well established in treating active Crohn’s disease, corticosteroids inhibit T-cell 
activation and cytokine production, are highly efficacious, induce remission in 60% 
and are recommended in many international guidelines (Summers 1979).  
Budesonide is effective in inducing remission in active Crohn’s disease and although 
less efficacious than prednisolone or hydrocortisone does have a more favourable 
side effect profile (Rezaie 2015).  Despite their efficacy steroids have short term 
effects only, relapse is common on stopping treatment and they are ineffective for 
maintenance of remission (Ford 2011a).  
 
1.9.3 Immunosuppressants 
Thiopurines block Rac1 activation which leads to apoptosis of T-cells and thereby 
imparts their well documented immunosuppressive effects (Tiede 2003).  Efficacy in 
maintaining remission of Crohn’s disease was confirmed in a Cochrane review 
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(Prefontaine 2009), however in a further systematic review were not shown to  be 
superior to placebo in inducing remission (Chande 2013).  In their 2002 paper 
Dubinsky et al investigated why nearly half of patients with active disease and one 
third of patients with quiescent disease fail to induce/maintain remission with 
thiopurines.  They found response to be associated with achieving a therapeutic 6-
thioguanine (6-TGN) concentration (>235pmol/8x108 red cells), that only 28% of 
non-responders gain benefit from dose escalation, and in the remainder that dose 
increase does not raise 6-TGN levels (Dubinsky 2002). Co-prescription of allopurinol 
with thiopurines shifts drug metabolism, has been shown to increase 6-TGN levels, 
and 66% of patients with previous thiopurine failure respond to treatment (Smith 
2012).  Routine early use of azathioprine does not lead to better outcomes than 
conventional use in terms of: time spent in remission, need for biologic treatment 
or the need for surgery (Cosnes 2013).  
 
1.9.4 Anti TNFs 
TNFα antagonists bind both soluble and transmembrane bound TNF and leading to 
2 main modes of action; i) induction of M2 wound healing macrophages and ii) 
induction of T-cell apoptosis and downregulation of CD40 dependent immune 
response (Danese 2006; Levin 2016). T-cell apoptosis is dependent on the 
concurrent presence of CD14+ macrophages expressing membrane bound TNF and 
only occurs with infliximab, adalimumab and certolizumab (drugs with proven 
clinical efficacy) but not with etanercept (previously shown only to be equivalent to 
placebo in treating active Crohn’s disease) (Atreya 2011).   
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Infliximab and adalimumab remain the main two anti-TNFα drugs in clinical use in 
the UK, have proven efficacy in inducing and maintaining remission, can lead to 
mucosal healing and reduce complications of Crohn’s disease including 
hospitalisation and surgery (Terdiman 2013).  Combination with thiopurines is 
superior to monotherapy in achieving clinical response, steroid free remission and 
mucosal healing (Colombel 2010).  Standard dosing is weight based and much 
interest surrounds the use of trough drug levels to guide treatment, but clinical 
utility remains uncertain with a recent prospective trial of dose adjustment based 
on trough levels failing to show any superiority in achieving disease remission 
(Vande Casteele 2015). 
 
1.9.5 Newer biologic drugs 
Vedolizumab, a monoclonal antibody which blocks alpha4beta7 interaction with 
MAdCAM-1 on endothelial cells and thereby prevents leucocyte trafficking to the 
gut, is superior to placebo in inducing clinical remission (defined by Crohn’s disease 
activity index (CDAI) ≤150) in a mixed population of patients with active Crohn’s 
disease (the Gemini II study, which included a proportion of anti-TNF refractory 
patients) at 6 weeks (14.5% vs 6.8%), maintained through to week 52 in 36-39% 
(Sandborn 2013).  In a group of patients all of whom were refractory to anti-TNF 
treatment (Gemini III) efficacy was again seen, although the onset of action was 
slower with superiority over placebo in achieving clinical remission seen only at 10 
weeks (but not at 6 weeks) (Sands 2014). 
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Ustekinumab, a monoclonal antibody directed against the common p40 subunit of 
IL12 and Il23, achieved clinical response in patients with anti-TNF treatment failure 
in a phase 2b trial and a recent follow on phase 3 trial has demonstrated efficacy 
relative to placebo with response rates of around 33% and remission in 15-20% 
(Sandborn 2016; Sandborn 2012). 
 
1.9.6 Diet and nutritional therapies 
Exclusive enteral nutrition is effective in inducing remission in Crohn’s disease and 
on a per-protocol basis achieves response rates equivalent to steroids (Zachos 
2007).  Tolerance remains a significant issue but even when only used to provide 
50% of calorie intake it is effective in maintaining remission (Akobeng 2007).   
Manipulation of a normal diet including exclusion diets (milk, dairy products, wheat, 
foods high in insoluble fibre), diets low in sugar and diets low in fats have not 
consistently been shown to confer clinical benefit (Richman 2013).  In complex 
Crohn’s disease exclusive total parenteral nutrition may achieve disease control 
(Ostro 1985), possibly analogous to the benefit seen in distal disease following 
defunctioning surgery (Burman 1971). 
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1.9.7 Antibiotics 
Antibiotics are quite commonly used to treat Crohn’s disease, and in light of the 
observed changes in gut microbiota might be expected to have therapeutic benefit.  
Multiple clinical trials have assessed this issue (summarised in Table 2-5) but overall 
there is little evidence to support their use (Khan 2011) except for the following; 
nitroimidazoles are effective at preventing post-operative disease recurrence 
(Rutgeerts 1995), ciprofloxacin and metronidazole benefit perianal disease (Khan 
2011) and may benefit colonic but not ileal disease (Perencevich 2006).  The choice 
of antibiotic used in clinical trials has historically been largely empiric but in vitro 
studies show efficiency of targeted therapy against intra-macrophage bacteria and 
further trials are now ongoing (Subramanian 2008).  
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Table 2: Trials of antibiotics in active Crohn’s disease 
  
Treatment Control Treatment 
duration 
Blinding N= Endpoint Treatment 
response 
Control 
response 
Significance Reference 
Metronidazole  Placebo 2 months Double 22 Point score Equal to 
placebo 
Equal to 
treatment 
NS (Blichfeldt 
1978) 
Metronidazole  Placebo 16 weeks Double 105 CDAI <150 36% 
 
25% NS (Sutherland 
1991) 
Ciprofloxacin  Pentasa 6 weeks Nil 40 CDAI <150 56% 55% NS (Colombel 
1999) 
Ciprofloxacin  Placebo 6 months Nil 47 Mean CDAI  Mean CDAI 
111 
 
Mean CDAI 
205 
P<0.001 (Arnold 2002) 
Ciprofloxacin + 
Metronidazole  
Nil 10 weeks Nil 72 HBI≤3 68% n/a n/a (Greenbloom 
1998) 
Metronidazole + 
Ciprofloxacin + 
Budesonide  
Budesonide 8 weeks Double 134 CDAI <150 33% 
 
 
38% NS (Steinhart 
2002) 
Metronidazole + 
Ciprofloxacin  
Nil 4 weeks Nil 7 Improvement n/a n/a n/a (Ishikawa 
2003) 
Metronidazole OR 
Cotrimoxazole OR 
Metronidazole + 
Cotrimox 
Placebo 2 weeks Nil 72 Clinical 
Improvement 
67% 
17% 
71% 
35% NS (Ambrose 
1985) 
Clarithromycin  Nil 4-12 weeks Nil 25 HBI≤3 4 week 
48% 
12 week 
44% 
n/a n/a (Leiper 2000) 
Clarithromycin  Nil 4-24 weeks Nil 14 CDAI <150 4 weeks 
36% 
24 week 
29% 
n/a n/a (Inoue 2007) 
Clarithromycin Placebo 3months Nil 41 CDAI <150 26% 27% NS (Leiper 2008) 
Rifaxamin bd OR 
Rifaxamin od 
Placebo 12 weeks Double 83 CDAI <150 52% 
32% 
33% NS (Prantera 
2006) 
Rifaximin 400mg bd 
OR 
Rifaximin  800mg 
bd OR 
Rifaximin 1200mg 
bd 
Placebo 12 weeks Double 402 CDAI <150 54% 
62% 
47% 
43% 800mg dose 
only, p<0.005  
(Prantera 
2012) 
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Table 3: Trials of antibiotics targeted against MAP in Crohn's disease  
Treatment Control Treatment 
duration 
Blinding N= Endpoint Treatment 
response 
Control 
response 
Significance Reference 
Clarithromycin + 
Rifabutin + 
Clofazimine 
Placebo 2 years or 
until 
relapse 
Double 213 Relapse 12 months 39% 
24 months 26% 
36 months 59% 
52% 
43% 
50% 
NS 
NS 
NS 
(Selby 
2007) 
Rifabutin + 
Clarithromycin +/- 
Ciprofloxacin, 
Ofloxacin or 
Clofazimine 
Nil Mean of 
18 months 
Nil 46 HBI <5 93.5% n/a n/a (Gui 1997) 
Rifampicin + 
Ethambutol + 
Dapsone + 
Clofazimine  
Placebo 9 months Double 40 Treatment 
failure 
13% relapse 61% relapse P<0.05 (Prantera 
1994) 
Ethambutol + 
Clarithromycin  
Placebo 3 months Double 31 Persistent 
active 
disease  
33% active 44% active NS (Goodgame 
2001) 
Rifampicin + 
Isoniazid + 
Ethambutol  
Placebo 2 years Double 130 Composite 
effects 
No difference No difference NS (Swift 
1994) 
Rifampicin + 
Isoniazid + 
Ethambutol  
Placebo 5 years 
follow up 
Double 130 Relapse 39% 43% NS (Thomas 
1998) 
Ethambutol + 
Rifampicin  
Placebo 1 year Double 27 Mean CDAI 183 156 NS (Shaffer 
1984) 
Rifabutin + 
Clarithromycin  
Nil 4-17 
months 
Nil 36 Fall in CDAI 58.3% n/a n/a (Shafran 
2002) 
Clarithromycin  Nil 3 months Nil 15 Remission 71% n/a n/a (Graham 
1995) 
Clofazimine +  
Corticosteroids 
Placebo 12 months Nil 49 Remission 64% 50% NS (Afdhal 
1991) 
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Table 4: Trials of antibiotics in perianal Crohn's disease 
 
 
 
 
 
 
Table 5: Trials of antibiotics as post-surgery prophylaxis  
Treatment Control Treatment 
duration 
Blinding N= Endpoint Treatment 
response 
Control 
response 
Significance Reference 
Ciprofloxacin + 
Metronidazole + 
Azathioprine 
Nil 8 weeks Nil 52 Response 35% n/a n/a (Dejaco 
2003) 
Ciprofloxacin + 
Infliximab 
Placebo +  
Infliximab 
12 weeks Double 24 50% 
reduced 
fistulae 
73% 39% NS (West 
2004) 
Ciprofloxacin OR 
Metronidazole  
Placebo 10 weeks Nil 25 Remission 30% 
0% 
12.5% NS (Thia 2009) 
Metronidazole 
ointment 
Placebo 4 weeks Double 74 Fall in 
PCDAI 
Equal Equal NS (Maeda 
2010) 
Treatment Control Treatment 
duration 
Blinding N= Endpoint Treatment 
response 
Control 
response 
Significance Reference 
Metronidazole Placebo 3 months Double 60 Recurrence 52% 75% NS (Rutgeerts 
1995) 
Ornidazole Placebo 1 year Double 81 Recurrence 7.9% 37.5% P<0.005 (Rutgeerts 
2005) 
Metronidazole + 
Azathioprine 
Metronidazole 3 months Nil 81 Recurrence 55% 78% P<0.05 (D'Haens 
2008) 
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1.9.8 Surgery and the risk of disease recurrence 
Generally indicated for stricturing or penetrating disease unresponsive to medical 
therapy, surgery is commonly required but is not curative and endoscopic 
recurrence, quantifiable using the Rutgeerts’ score, occurs in 85% by 3 years 
(Rutgeerts 1990).  Smoking, penetrating disease behaviour, ileocolonic disease 
location, short interval between diagnosis and first surgery and young age are all 
associated with an increased risk of recurrence after surgery (Lautenbach 1998).  
The risk of recurrent disease is reduced by the use of immunomodulators in high 
risk patients and by performing routine colonoscopy at 6 months followed by 
treatment escalation in patients with early disease recurrence (De Cruz 2015).  
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2 Innate Immune system in Crohn’s disease and its interaction with 
the microbiome 
2.1 Implications of gene association studies for innate immune function 
Arguably, the biggest contribution of GWAS studies to the understanding of Crohn’s 
disease pathogenesis has not been to address issues of hereditability but to identify 
previously unknown or little considered biological pathways with relevance for 
disease pathogenesis.  Of particular interest has been the light shone on the innate 
immune system including autophagy, the adaptive immune system and barrier 
function. 
 
2.1.1 Autophagy and macrophage function 
Autophagy, the process whereby a double membraned autophagosome is formed 
in the cytoplasm and subsequently fuses with a lysosome to degrade cytosolic 
components, is a key mechanism in cellular homeostasis both in health and disease 
and represents an important pathway for clearing intracellular bacteria.  Variants in 
autophagy-related 16-like 1 (ATG16L1) and immunity-related GTPase M (IRGM) are 
associated with increased risk for Crohn’s disease. 
The strongest genetic association with Crohn’s disease is with polymorphisms and 
deletions in NOD2/CARD15, conferring a relative risk for developing Crohn’s disease 
of 2.13-3.03 (Liu 2015).  The NOD2 protein acts as an intracellular receptor for 
muramyl dipeptide (MDP), a component of Gram-negative and Gram-positive 
40 
 
bacterial cell wall peptidoglycan, leading to production of Paneth cell defensins, 
which have a potent antimicrobial effect (Gaya 2006; Wehkamp 2005).  MDP-
engaged NOD2 also plays an important role in autophagosome generation, 
recruiting ATG16L1 to the cell-surface membrane where bacterial engulfment is 
occurs.  Crohn’s related mutations in NOD2 have complex effects  including 
impaired autophagy (via a failure to recruit ATG16L1) and bacterial killing by 
macrophages, reduced mononuclear cell IL-8 response to bacteria and reduced 
defensin production by Paneth cells (Wehkamp 2005).  Loss of ATG16L1 and IGRM 
function has also been shown to alter Paneth cell granule morphology (Cadwell 
2008), to increase interleukin 1β production and allow enhanced intracellular 
bacterial survival (Lees 2009). 
Patients who are homozygous for NOD2 polymorphisms and patients who are 
homozygous for ATG16L1 polymorphisms have macrophages that are deficient at 
killing phagocytosed bacteria  and also have increased levels of circulating bacterial 
DNA, implying increased bacterial translocation (Gutierrez 2014).   
 
2.1.2 Evidence for failure of adequate bacterial clearance in Crohn’s disease 
It is worth noting that as many as one third of patients with Crohn’s disease in 
remission, most of whom have no NOD2 or ATG16L1 abnormality, have evidence of 
circulating bacterial DNA, particularly Gram-negative organisms, and that this 
correlates with substantially increased risk for subsequent relapse (Gutierrez 2014).  
This is in keeping with fact that macrophages are at best rather ineffective at killing 
bacteria in comparison with neutrophils (Hoidal 1981).   
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2.1.3 Intra-macrophage bacterial replication and the development of disease  
There is growing evidence for intra-vesicular replication of bacteria such as E. coli 
within Crohn’s tissue macrophages.  Studies by Ryan et al , for example, used laser 
capture on Crohn’s tissue sections to show that the majority of Crohn’s disease 
granulomata contained E. coli DNA, whereas control granulomata did not (Ryan 
2004).  This reflects similarities with conditions such as Q fever and Whipple’s 
disease, where intramacrophage replication of bacteria inside macrophage 
phagosomes - Coxiella burnetii and Tropheryma whipplei respectively - is central to 
pathogenesis.  In these conditions the organisms exhibit different ways in which 
they circumvent killing by the macrophages.  Tropheryma whipplei resides within a 
phagosome prevented from maturation by blocking the switch from Rab5 to Rab7 
so that the phagosomes are unable to fuse with lysosomes (Mottola 2014).  C 
burnetii however is able to replicate within phagolysosome-like vacuoles (Winchell 
2014).  
 
2.1.4 Macrophage function and neutrophil chemotaxis 
It is important to note though that even healthy macrophages are very poor at 
killing some phagocytosed bacteria, including E. coli and Mycobacterium spp., and 
bacterial killing is performed much more efficiently by neutrophils.  Segal and 
colleagues have suggested that much of the problem in Crohn’s disease arises as a 
result of defective neutrophil chemotaxis towards sites of inflammation.  They have 
shown very marked reduction in neutrophil chemotaxis into patient’s serum within 
Perspex windows placed over abraded skin and have also shown slow neutrophil 
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recruitment into colonoscopic biopsy lesions as well as delayed recruitment of 
radiolabelled neutrophils to intradermally injected dead E. coli.  In separate 
experiments monocyte-derived macrophages demonstrated attenuated cytokine 
production in response to E. coli infection and toll-like receptor stimulation 
suggesting that the delayed neutrophil chemotaxis may arise as the result of 
defective macrophage cytokine responses (Marks 2006; Sewell 2012; Smith 2009).  
2.2 The role of the microbiome 
There is general consensus that the gut microbiota are involved in some way in 
Crohn’s disease pathogenesis even though there is no strong evidence for any 
specific pathogen. This is supported by the fact that a wide range of animal models 
of inflammatory bowel disease, many based on knockouts of specific immune-
related genes, all require the presence of normal commensal bacteria to develop 
inflammation. 
The total human gut microbiome consists of around 1,150 bacterial species, the 
majority of which cannot be cultured and have been identified using molecular 
techniques.  Each individual typically hosts around 160 species (Qin 2010).  Gut 
colonisation is established within the first two weeks of life with further changes on 
weaning and then usually remains remarkably stable over time (Hoogkamp-
Korstanje 1979).  It is important to note that the mucosal and faecal microbiomes 
consist of distinct bacterial populations and mucosa-associated bacteria may be 
more important in IBD (Eckburg 2005).   
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2.2.1 Faecal microbiota 
Many independent groups have now consistently found differences in the faecal 
microbiome in patients with IBD compared to healthy controls.  Firstly there is a 
significantly reduced biodiversity (reduced by about 25%) in Crohn’s disease with 
changes in the dominant organisms.  Secondly, whilst the microbiota in health 
remains stable over time, significant temporal variations are seen in IBD.  
Furthermore, significant inter-individual differences are seen in IBD more than in 
health (Joossens 2011; Manichanh 2006; Scanlan 2006; Seksik 2003). 
In health the Firmicutes and Bacteroidetes phyla predominate and contribute to the 
production of epithelial metabolic substrates including butyrate (Backhed 2005).  By 
contrast in Crohn’s disease changes are observed in the microbiota characterised by 
a relative lack of Firmicutes (specifically a reduction in Clostridium leptum) and 
Bacteroidetes with an over-representation of Enterobacteria (including Escherichia 
coli), which may conceivably alter epithelial homeostasis.  Relapses in Crohn’s 
disease have been commonly reported in association with pathogenic infections 
such as Campylobacter and Salmonella gastroenteritis (Irving 2008).   
It is conceivable that some of these observed variations arise as a result of 
environmental and dietary influences but family and twin studies suggest they are 
disease specific.  In families with at least 3 members affected by Crohn’s disease 
there were still significant differences in the faecal microbiota of patients compared 
to unaffected family members (Joossens 2011).  These findings are supported by a 
study in which monozygotic twins discordant for Crohn’s were shown to have 
significantly different faecal microbiota with a reduction in biodiversity seen in 
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Crohn’s disease – a change most marked in patients with ileal disease (Dicksved 
2008).  
It is however notable that changes in faecal microbiota are also seen in infectious 
colitis and in models of inflammation such as dextran sulphate sodium (DSS) 
induced colitis (Nanda Kumar 2008) so the faecal dysbiosis may arise at least in part 
as a consequence of inflammation rather than as a primary event (Sokol 2006).  
 
2.2.2 Mucosa-Associated Bacteria 
More specific changes have been found in the mucosa-associated microbiota in 
Crohn’s disease.  In the healthy colon there is a continuous mucus coating 
consisting of two layers, the outer of which is loosely adherent and has a favourable 
environment for bacterial growth but the inner tightly adherent layer is normally 
sterile.  In the small intestine the adherent layer is much thinner and probably 
discontinuous.   In IBD, particularly Crohn’s disease, there is a marked increase in 
bacteria associated with the colonic adherent mucus layer (Johansson 2008; Ott 
2004; Swidsinski 2002).   
In Crohn’s disease consistent increases in mucosa-associated Proteobacteria 
(including E. coli) and reductions in Firmicutes are reported but results for 
Bacteroidetes vary between studies (Frank 2007; Martinez-Medina 2006; Ott 2004).  
There is strong evidence for an increase in mucosal associated E. coli in both the 
ileum and colon and their presence within Crohn’s granulomas, as previously 
mentioned, argues for a primary pathogenic role (Ryan 2004).  Crohn’s disease E. 
45 
 
coli isolates tend to have an adherent and invasive (AIEC) phenotype typified by 
invasion of epithelial cells and replication within macrophages (Glasser 2001).  
However the AIEC phenotype lacks an associated genotype and is defined using 
invasion into an epithelial cell line, I407, which is now known to be a transformed 
cervical cancer cell line of uncertain relevance.  Moreover replication within 
macrophages is seen with the majority of human intestinal E. coli isolates, not just 
those with the ability to invade I407 (O'Brien 2016).  Mucosal E. coli have been 
shown to induce formation of multi-nucleated giant cells with granulomatous 
morphology in vitro and E. coli with a similar phenotype induce granulomatous 
colitis in Boxer dogs (Meconi 2007; Simpson 2006).    
 
2.2.3 Faecalibacterium prauznitzii 
In ileal Crohn’s disease both mucosal and faecal bacterial studies have 
demonstrated reduced levels of the Firmicute, Faecalibacterium prauznitzii (F. 
prau), a member of the Clostridium leptum group.   In patients with ileal Crohn’s 
disease a strong association is seen with depleted F. prau in biopsies taken from the 
colon and ileum and this is not the case for colonic disease.  This reduction in F. 
prau appears to be associated with a concomitant increase in ileal and colonic E. 
coli  (Willing 2009).  This may be clinically relevant as low levels of mucosa-
associated F. prau are associated with a much greater risk of recurrent Crohn’s 
disease following surgery and the bacteria and its supernatant are able to reduce 
severity of chemical (TNBS)- induced colitis in murine models (Sokol 2008).  
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2.2.4 Specific factors affecting the microbiome 
Smokers have demonstrable differences in their faecal microbiome relative to non-
smokers and healthy controls, perhaps of relevance when considering the increased 
risk of disease in current and previous smokers (Benjamin 2012).  
Unaffected siblings of patients with Crohn’s disease have been shown to have both 
a mucosa-associated microbiome and faecal microbiome significantly different to 
both affected relatives and healthy controls.  This variation is typified by a 
reduction in diversity and fewer Faecalibacterium prausnitzii (F. prau) although it is 
notable that intestinal permeability was normal in healthy siblings (Hedin 2016; 
Hedin 2014). 
2.3 M cells as a portal of entry 
M (microfold) cells are specialised epithelial cells which account for about 5-10% of 
the dome epithelium overlying Peyer’s patches in the distal ileum and lymphoid 
follicles in the colon.  They represent the major portal of entry for invasive gut 
pathogens and it is likely that they are also the initial portal of entry by which E. coli 
are able to invade (Sansonetti 1999).  In support of this, the aphthoid ulcers that 
are the earliest lesions of Crohn’s disease are commonly seen to overly Peyer’s 
patches and lymphoid follicles (Fujimura 1996).  Moreover there is a striking 
correlation between the age-related incidence of Crohn’s disease and the number 
of Peyer’s patches in the small bowel, the latter peaking in late adolescence and 
then falling away (Van Kruiningen 1997).  Crohn’s disease mucosal E. coli isolates 
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more frequently express long polar fimbriae (lpfA) that are essential for 
translocation across M cells (Prorok-Hamon 2014).  
2.4 Summary of possible interaction between immune system and infection 
in Crohn’s disease 
In conclusion, although convincing evidence for a specific pathogen is lacking, there 
is growing evidence to suggest that a combination of mucosa-associated E. coli, well 
adapted for replication within macrophages, and a lack of probiotic 
Faecalibacterium prausnitzii, combine with inborn or acquired defects in immune  
or barrier function to lead to the development of Crohn’s disease.  
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3 Hypothesis and Aims 
3.1 Hypothesis 
Mucosal E. coli isolates, which have ability to survive and replicate within 
intracellular vesicles, are able to persist within macrophages and this may represent 
a primary pathogenic event in Crohn’s disease.  Gene associations with Crohn’s 
disease also imply defective innate immunity including macrophage function. 
Hydroxychloroquine is known to enhance killing of other intracellular organisms 
and may similarly facilitate macrophage killing of E. coli.  Vitamin D enhances 
immune cell function and may also improve macrophage killing of phagocytosed E. 
coli. 
The hypotheses explored in this thesis are that: 
1. Defective macrophage killing of bacteria, particularly E. coli, may be an 
underlying pathogenic mechanism in Crohn’s disease. 
2. Hydroxychloroquine treatment may enhance the ability of murine and 
human macrophages to kill intracellular E. coli and this effect may be 
synergistic with antibiotics. 
3. Hydroxychloroquine may lead to enhanced killing of intracellular bacteria by 
favourably altering the macrophage intracellular environment. 
4. Vitamin D supplementation may enhance the ability of macrophages to kill 
intracellular bacteria. 
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3.2 Aims 
1. To determine the ability for E. coli to survive within murine and human 
(including Crohn’s disease and control) macrophages and to assess their 
cytokine and chemokine responsiveness. 
2. To determine the effect of hydroxychloroquine treatment on the survival of 
E. coli within murine macrophages 
3. To determine the mechanisms by which hydroxychloroquine acts on 
intracellular organisms 
4. To determine the effect of hydroxychloroquine on bacterial survival in 
human monocyte derive macrophages 
5. To determine the effects of Vitamin D supplementation on intramacrophage 
bacterial survival 
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4 Materials and Methods 
4.1 Materials 
Unless otherwise stated all materials were obtained from Sigma-Aldrich (Poole, UK).   
4.2 Ethical approval 
Ethical approval for this study was obtained from the National Research Ethics 
Service (NRES) Committee North West (Study number 09/H1010/64).   
4.3 Patient recruitment 
Patients were recruited from the Royal Liverpool University Hospital (RLUH) and 
healthy controls recruited from both RLUH and the University of Liverpool.  A 
summary of inclusion/exclusion criteria and patient characteristics is included 
supplementary appendix 1 (Table 8-10).  Baseline characteristics varied only in the 
level of high sensitivity CRP (hsCRP) (higher in CD group) but were otherwise 
equivalent.  Five of the CD patients had active disease as defined by Harvey 
Bradshaw index (HBI) >4 (Vermeire 2010a).  None of the CD patients were receiving 
immunosuppressants, corticosteroids or anti-TNFα therapy and none had features 
suggestive of sepsis (median hsCRP 5.9mg/L, range 1.04-18.3). 
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4.4 Bacterial strains and culture 
4.4.1 Bacterial strains 
Two representative CD mucosa-associated Escherichia coli isolates were studied; 
both conform to the original AIEC phenotype: HM605, an isolate from the colonic 
mucosa of a patient with CD (Martin 2004), and LF82, isolated from an ileal lesion of 
a French patient with CD (Boudeau 1999) (kindly gifted by the late Prof. A. 
Darfeuille-Michaud, Pathogénie Bactérienne Intestinale, Clermont-Ferrand, France).  
Both have been shown to survive and replicate within the phagolysomes of murine 
and peripheral blood monocyte-derived macrophages (Bringer 2006; Mpofu 2007; 
Subramanian 2008).  In addition, two laboratory strains of E.coli; K-12 (ATCC 29425, 
Manassas, VA, USA) and K-12 derivative EPI300™-T1R (Epicentre BioTechnologies, 
Madison, WI, USA), and Staphylococcus aureus (S. aureus) Oxford strain (NCTC 
6571, Public Health England, Porton Down, UK), acted as controls. 
  
52 
 
4.4.2 Bacterial culture 
Isolates were cultured overnight on Luria Bertani (LB) agar (Table 6) at 37oC in air.  
After overnight culture, isolates were washed three times, resuspended in sterile 
phosphate buffered saline (PBS) pH 7.3, and adjusted by optical densitometry 
(OD550nm) to a desired final concentration (for macrophage killing assays; 1x10
9/mL, 
for flow cytometry; 1x1010/mL). 
Bacteria were freshly cultured and placed in suspension for each experiment.  On 
each occasion the concentration of bacterial in suspension was confirmed by 
plating in triplicate onto LB agar, incubating overnight at 37oC in air, and finally 
enumerating colony forming units (CFU). 
 
 
 Table 6: Constituents of LB agar 
 
  
Constituent  
(made up to 1000mls with deionised water) 
Manufacturer 
10 g Bacto™ Tryptone Becton Dickinson (New Jersey, USA) 
5 g Bacto™ Yeast Becton Dickinson (New Jersey, USA) 
5 g NaCl Sigma-Aldrich 
15g Agar Sigma-Aldrich 
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4.4.3 Standard curves of bacterial concentration in solution 
In order to reliably produce accurate concentrations of bacteria in suspension using 
optical density (OD), standard curves of bacterial concentration against OD550nm 
were generated for each strain used (Figure 4-1-4-3).   
Following overnight culture, washing and suspension in PBS, serial dilutions of 
concentrated bacterial suspensions were performed.  For each dilution the OD550nm 
was measured before plating in triplicate onto LB agar and then enumerating 
colony forming units (CFUs) after overnight culture.  Each experiment was 
performed in triplicate and average values used to generate the curves. 
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Figure 4-1: Standard curve for Escherichia coli HM605 against OD550nm 
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Figure 4-2: Standard curve for Escherichia coli K12 against  OD550nm 
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Figure 4-3: Standard curve for Staphylococcus aureus Oxford strain against OD550nm 
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4.4.4 Bacterial growth in broth 
Bacterial growth dynamics were determined by incubation of bacteria in broth.  
1x107 bacteria were added to RPMI-1640 supplemented with 10% vol/vol FBS and 
2mM Glutamine plus hydroxychloroquine (0-10μg/mL) or vehicle control, and 
maintained at 37oC on an orbital incubator at 150rpm in air.  Optical density 
(OD600nm) was determined each hour.  In separate experiments samples were 
obtained every two hours and plated onto LB agar plates to confirm bacterial 
viability. 
 
4.4.5 Minimum inhibitory concentration testing 
For each E. coli strain the minimum inhibitory concentrations (MIC) for ciprofloxacin 
and doxycycline were determined using Etest® stable gradient antibiotic strips 
(Biomerieux, Basingstoke, UK).  Following overnight culture on LB agar at 37oC in 
air, E. coli isolates were washed three times, resuspended in sterile PBS, adjusted to 
MacFarlane standard 0.5 and streaked onto LB agar plates.  Etest® strips were 
applied, plates incubated overnight and results read the following day according to 
the manufacturer’s instructions (Figure 4-4 and 4-5). 
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Figure 4-4: Representative image of minimum inhibitory concentration testing for 
ciprofloxacin against E. coli strains using Etest® strips 
 
 
 
 
Figure 4-5: Representative image of minimum inhibitory concentration testing for 
doxycycline against E. coli strains using Etest® strips 
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4.5 Mammalian Cell culture 
Unless otherwise stated Corning Costar tissue culture (Tewksbury, MA, USA) plates 
were used, obtained from Fisher Scientific (Loughborough, UK). 
 
4.5.1 J774A.1 murine macrophages 
J774A.1 murine macrophages, (# 91051511) were obtained from the European 
Collection of Cell Cultures (Porton Down, Wiltshire, UK). Cells were cultured in 
75cm2 flasks and maintained at 37oC in Roswell Park Memorial Institute-1640 
medium (RPMI-1640) supplemented with 10% vol/vol foetal bovine serum (FBS), 
2mM glutamine, 50U/mL Penicillin and 50µg/mL Streptomycin (complete RPMI), in 
a humidified atmosphere of 5% CO2/95% air.  Macrophages were passaged by 
scraping twice weekly, up to passage 19. 
  
58 
 
4.5.2 Human monocyte-derived macrophages 
50mls of peripheral blood was obtained from consenting volunteers and mixed 
immediately with unfractionated heparin sodium (Wockhardt UK Ltd, Wrexham, 
Wales) to a final concentration of 5units/ml.  Heparinised blood was mixed with an 
equal volume of sterile PBS (Life Technologies, Paisley, UK), layered over 
Lymphoprep™ density gradient medium (Alere, Stockport, UK) in 50ml 
polypropylene tubes (Greiner Bio-One, Stonehouse, UK) at a ratio of 2 parts 
blood/PBS to 1 part Lymphoprep.  A mononuclear cell layer was then generated by 
centrifugation at 800 x g for 20minutes at room temperature with brakes 
minimised (Figure 4-6).  The resulting mononuclear cell layer was carefully 
aspirated, transferred to a clean 50ml tube and twice washed in sterile PBS by 
centrifugation at 400 x g for 10mins at room temperature.  Cells were resuspended 
in RPMI-1640 medium supplemented with 20mM Hepes, 100U/mL Penicillin and 
100µg/mL Streptomycin, adjusted to 5x106/ml, seeded into 100mm Nunc™ cell 
culture dishes (VWR International, Lutterworth, UK) and cultured at 37oC in a 
humidified atmosphere of 5% CO2, 95% air for 2hours.  Non-adherent cells were 
removed by washing twice with sterile PBS and adherent monocytes then 
differentiated into macrophages by 5 day culture at 37oC in RPMI-1640 medium 
supplemented with 10% vol/vol FBS, 20mM Hepes, 100U/mL Penicillin and 
100µg/mL Streptomycin, in a humidified atmosphere of 5% CO2, 95% air as per 
(Smith 2009).  
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Figure 4-6: Photograph (left) and diagram (right) showing mononuclear cell 
isolation after centrifugation over Lymphoprep™ density gradient medium 
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4.5.3 Genomic analysis for CD-associated polymorphisms in NOD2, ATG16L1 
and IRGM 
EDTA peripheral venous blood samples were taken from the CD patients and 
healthy controls in whom macrophage function studies were performed, genomic 
DNA extracted using a Nucleon® BACC3 kit (Gen-Probe, Livingston, UK), yield 
determined using PicoGreen® (Life Technologies) and samples normalised to final 
DNA concentration of 10ng/μL.  DNA was analyzed by TaqMan® system (Applied 
Biosystems, Foster City, CA, USA) in the Wellcome Trust Clinical Research Facility 
Edinburgh, (Western General Hospital, Edinburgh, UK) for NOD2 (rs2066844, 
rs2066845 and rs2066847) (Barrett 2008; WTCCC 2007), ATG16L1 (rs2241880) 
(Cooney 2010; Rioux 2007) and IRGM (rs13361189) (Parkes 2007) as previously 
described (Van Limbergen 2008). 
 
4.5.4 Human neutrophils 
50mls of peripheral blood was obtained from healthy consenting donors and 
heparinised to a final concentration of 5units/ml.  Heparinised blood was layered 
over Polymorphprep™ (Alere, Stockport, UK) in a ratio of 1 part blood to 1 part 
Polymorphprep in 50ml polypropylene tubes then centrifuged at 500 x g for 
35minutes at room temperature with brakes minimised (Figure 4-7).  After careful 
removal of the mononuclear cell layer neutrophils were aspirated, transferred to a 
clean 50ml tube, resuspended in RPMI supplemented with 20mM Hepes, 0.5% 
vol/vol bovine serum albumin (BSA), 2mM CaCl2 and 2mM MgCl2 and centrifuged at 
500g for 5 min at room temperature.  After careful removal of the supernatant, 
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cells were resuspended in 3mls of supplemented RPMI and 27mls of sterile red cell 
lysis buffer (13.4mM potassium bicarbonate, 155mM ammonium chloride, 96.7μM 
EDTA in deionised water), allowed to stand for 3minutes to lyse red cells and then 
centrifuged at 400 x g for 3minutes.  Finally the supernatant was discarded, the 
isolated neutrophils were resuspended in supplemented RPMI and then used 
immediately. 
 
Figure 4-7: Diagram demonstrating resultant cellular layers allowing isolation of 
neutrophils after centrifugation of heparinised blood over Polymorphoprep™ density 
gradient medium 
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4.5.5 Assessment of cellular cytotoxicity  
Release of intracellular adenylate kinase, as a marker of cell damage, was quantified 
over 6h following cellular treatment and/or bacterial infection using the Toxilight™ 
assay kit (Lonza, Slough, UK).  Assays were performed according to the 
manufacturer’s instructions in white walled, clear bottom, 96 well plates.  
Luminescence was measured on a Tecan F200 microplate reader (Tecan, 
Männedorf, CH).  Total cellular levels of adenylate kinsae were established using a 
Total Lysis kit (Lonza).  Release of adenylate kinase into the culture media was 
expressed as a proportion of total adenylate kinase release and was compared to 
untreated, vehicle-treated or uninfected controls. 
4.6 Intramacrophage bacterial replication 
4.6.1 J774A.1 murine macrophages 
Replication of Crohn’s associated E. coli within J774A.1 murine macrophages was 
assessed by culture and lysis after gentamicin killing of non-internalised bacteria.  
Cells were seeded in triplicate into 24 well plates at 105 cells per well in fully 
supplemented RPMI-1640 medium and cultured for 24h at 370C, 5% CO2, 95% air.  
Prior to infection, monolayers were washed 3 times with sterile PBS, 800µL 
antibiotic-free RPMI added to each well and macrophages infected at a multiplicity 
of infection (MOI) of 10.  Following a 2h infection, macrophages were washed three 
times with sterile PBS and then treated for 1h in RPMI containing 20µg/mL 
gentamicin to kill non-internalised bacteria.  After 1h incubation macrophages were 
washed three times with sterile PBS then lysed with 1% vol/vol Triton X-100 in 
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deionised water for 5 min to release internalised bacteria.  Lysates were plated to 
LB agar and colony forming units (CFU) enumerated after overnight culture at 37oC 
in air.   
In order to assess relative killing (or replication) of phagocytosed bacteria, parallel 
plates were performed where macrophages were cultured for a further 3h in fresh 
medium following the 1h gentamicin treatment step (6h total), again followed by 
washing, lysis, overnight culture and colony counting.   
To calculate fold replication of E. coli within macrophages, the viable counts at the 
end of the final 3h incubation period (total 6h) were compared to viable CFU 
obtained from parallel plates lysed immediately after 1h gentamicin treatment (3h). 
Data were expressed as fold change of recovered intramacrophage bacteria at 6h 
relative to intracellular numbers at 3h.    
 
4.6.2 Human monocyte-derived macrophages 
Macrophages were generated from adherent monocytes as described above.  
Monolayers were washed twice with sterile PBS, cells detached by scraping and 
resuspended in antibiotic free X-Vivo 15 medium (Lonza, Slough, UK) then seeded in 
triplicate into 24 well plates at 105 cells per well before overnight culture.  Intra-
macrophage replication was determined used the technique described above with 
the modification of using a MOI of 25. 
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4.6.3 Effect of hydroxychloroquine on bacterial growth in broth 
Bacterial growth dynamics were determined by incubation of bacteria in broth.  
1x107 bacteria were added to RPMI supplemented with 10% FBS and 2mM 
glutamine and maintained at 37oC on an orbital incubator at 150rpm in air.  Optical 
density was determined each hour.  In separate experiments samples were 
obtained every two hours and plated onto LB agar plates to confirm bacterial 
viability. 
 
4.6.4 Effects of hydroxychloroquine, with and without antibiotics, and vitamin 
D on intra-macrophage survival of internalised Crohn’s-associated E. coli 
The effects of hydroxychloroquine, antibiotics and vitamin D on intra-macrophage 
bacterial survival were determined using the intra-macrophage bacterial replication 
assay described above. 
Hydroxychloroquine undergoes steady-state pharmacokinetics and doses were 
selected based on published steady state concentrations (Carmichael 2003; 
Munster 2002). 
Doxycycline and ciprofloxacin were tested both at Cmax (the peak serum 
concentration achieved with a standard oral dosing regimen) and 10% Cmax based 
on published data (Agwuh 2006; Gonzalez 1984; Saravolatz 2005) (Figure 6-4). 
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1,25OH2Vitamin-D3 concentrations were those defined as deficient in human serum 
(<20nM) (Hewison 2012; Rosen 2011) and that required for optimal immune cell 
function (>80nM) (Fabri 2011; Hewison 2012). 
 
4.6.5 Influence of intracellular iron availability on the action of 
hydroxychloroquine 
To determine whether the antibacterial actions of hydroxychloroquine (HCQ) were 
mediated through pH-mediated restriction of intramacrophage iron, macrophages 
were pretreated with either 10μM ferric citrate, which exhibits pH-dependent 
solubility and release of free ferric iron, or 10μM ferric nitrilotriacetic acid (FeNTA), 
which releases free ferric iron irrespective of pH, as per (Byrd 1991; Trinder 1998). 
 Ferric citrate was dissolved in sterile ultra-high quality (UHQ) water (18.2 MΩ-cm 
(0.05 µS) at 10 mg/mL, aliquoted and stored at -20oC until needed. FeNTA was 
formed by combining ferric chloride (100 mg/mL in 1N HCl) and nitrilotriacetic acid 
disodium salt (100 mg/mL in UHQ water) in equimolar quantities, diluting to 1mM 
with sterile UHQ water and adjusting to pH 7.4 with 1N NaOH, yielding 85% of 
monomeric FeNTA as per (Bates 1971). FeNTA was fresh on the day of each 
experiment to avoid any instability observed during storage. 
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4.7 Phagolysosomal pH 
4.7.1 Fluorescent microplate reader 
To assess for intraphagolysosomal pH changes effected by hydroxychloroquine, 
macrophages were monitored using two pH-sensitive fluorophores; pHrodo™ 
conjugated to E. coli bioparticles, fluorescent at acidic pH (Deriy 2009) and 
fluorescein isothiocyanate (FITC)-dextran, fluorescent at alkaline pH (Ohkuma 
1978).  J774A.1 macrophages seeded into white walled, clear bottomed 96-well 
plates at 5x105/mL, were maintained in supplemented RPMI-1640 media and 
cultured for 24h.  They were then washed three times with sterile PBS, followed by 
addition of 100µL of pHrodo™ E. coli bioparticles (0.1 mg/mL in phenol red-free 
Hank’s Balanced Salt Solution (HBSS) containing 20mM HEPES, pH 7.4), and infected 
for 2h with E. coli K-12 strain EPI300™-T1R at an MOI of 10.  Macrophages were 
then washed twice with sterile PBS and maintained in HBSS containing 
hydroxychloroquine (0-20 µg/mL) for a further 3h.  For FITC-dextran, this was added 
to macrophages wells prior to overnight culture to a final concentration of 1 
mg/mL.  Fluorescence was quantified using a Tecan F200 microplate reader using 
excitation/emission wavelengths of; 535nm excitation, 590nm emission for 
pHrodo™ and 485nm excitation, 535nm emission for FITC-dextran. 
For both fluorophores, a pH calibration curve was generated following incubation of 
fluorophore loaded macrophages in pH-calibrated phosphate-citrate buffers (range 
pH 4-8) containing 20μM nigericin, an ionophore which equilibrates intracellular pH 
with extracellular pH (Reijngoud 1975) (Figure 4-8 and 4-9).  Immediately after 
addition of calibration buffers, fluorescence emissions were measured as previously 
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detailed.  Readings were taken every 5 min for 1h.  Bafilomycin A1, a vacuolar H+ 
ATPase inhibitor (Bowman 1988) was used as a positive control for macrophage 
phagolysosome alkalinisation. 
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Figure 4-8: Standard pH calibration curve measuring fluorescence of 
intramacrophage pHrodo™ labelled E. coli bioparticles against solutions of known 
pH 
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Figure 4-9: Standard pH calibration curve measuring fluorescence of 
intramacrophage FITC against solutions of known pH 
 
 
4.7.2 Fluorescent microscopy 
Phagolyosomal pH was further assessed by fluorescent microscopy using dual 
labelled E. coli.  E. coli K12 (ATCC® 29425™, Manassas, VA, USA) grown overnight on 
LB agar were harvested, washed 3 times in sterile PBS, resuspended in 100mM 
Trehalose before freezing at -80oC and subsequent overnight lyophilisation.  
Viability of organisms recovered after lyophilisation was confirmed by re-
suspension and overnight culture.  Lyophilized E. coli K12 were then dual-labelled 
with Alexa Fluor® 350 (a pH-insensitive flurophore) (Life Technologies, Paisley, UK) 
and pHrodo™ red, succinimidyl ester (pH-sensitive, increasing fluorescence at acidic 
pH) (Life Technologies, Paisley, UK).  pHrodo™ in 100% anhydrous 
dimethylsuphoxide (DMSO) was added to E. coli re-suspended in 100mM sodium 
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bicarbonate (pH 8.5) to achieve a final concentration of 0.5mM and incubated on a 
rocking platform at room temperature for 45 min.  Subsequently, E. coli were 
washed twice with sterile HBSS, resuspended in sterile PBS (pH 9) and Alexa Fluor® 
350 in 100% anhydrous DMSO added to a final concentration of 0.5mM before 
incubation for 60 min.  Labelled bacteria were then washed with HBSS and 
resuspended in sterile PBS (pH 9) and either stored at 4oC and used with 3d, or 
frozen at -20oC for later use. 
Microscopy was performed on macrophages seeded onto 19mm coverslips in 12 
well tissue culture plates at 5x105 per mL, maintained in complete RPMI-1640 
medium and cultured for 24h.  Monolayers were washed three times with sterile 
PBS, treated with 1ml of antibiotic-free RPMI 1640 medium and infected with dual 
labelled E. coli K12 (MOI of 50).  Following 3h infection, cells were washed twice 
with sterile PBS, fixed with 2% vol/vol paraformaldehyde in PBS (Taab, Berks, UK), 
mounted in Vectashield mounting media (Vector Labs, Peterborough, UK) and 
imaged using an Olympus BX51 fluorescence microscope using excitation/emission 
wavelength of; 560 excitation, 630 emission for pHrodo™ and 360 excitation, 460 
emission for Alexa Fluor® 350.  Image processing was performing using AQM 6 
software (Kinetic imaging, Nottingham, UK). 
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4.7.3 Confocal microscopy 
Confocal microscopy was used to measure intra-organelle pH following 
hydroxychloroquine treatment of macrophages.  All confocal microscopy was 
performed using a Zeiss LSM 510 meta laser confocal microscope with an 
atmosphere- and temperature-controlled stage.  Images were processed using LSM 
5 software (Carl Zeiss AG, Oberkochen, Germany) and fluorescent intensity 
analysed with AQM 6 (Kinetic Imaging, Nottingham, UK). 
2x105 J774A.1 murine macrophages were seeded into 35mm CELLview™ tissue 
culture dishes (Greiner Bio-One, Stonehouse, UK) in 2mls RMPI supplemented with 
10% vol/vol FBS, 2mM Glutamine, 50U/mL Penicillin and 50µg/mL Streptomycin 
and cultured overnight.  Monolayers were washed three times with sterile PBS 
before adding 1.9mls phenol red-free, antibiotic-free RPMI (Life Technologies, 
Paisely, UK) containing  10μg/mL pHrodo™ E. coli bioparticles (suspended in phenol 
red-free Hanks Balanced Salt solution (HBSS) supplemented with 20mM HEPES, pH 
7.4) and incubated for 30mins at 37oC (Figure 4-10 to 4-12).  Monolayers were 
washed three times with sterile PBS then incubated in phenol red-free RPMI 
containing hydroxychloroquine (0-10μg/ml) for 3h.  NH4Cl(2mM) was used as an 
intra-phagolysosome alkalinisation control.  Finally, 10 high powered fields of view 
were imaged for each plate using a 63x oil immersion objective with optimisation of 
the focal plane to maximise fluorescent intensity on each occasion.   
To generate pH values from fluorescent intensity, standard curves were obtained.  
After overnight culture and 30min loading with pHrodo™ particles, monolayers 
were incubated for 30mins with calibration buffers containing 5mM Hepes, 120mM 
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KCl, 20mM NaCl, 1mM CaCl2, 1mM MgCl2, Nigericin 10μM, Vanilomycin 10μM, 
Bafilomycin 0.1μM adjusted to pH 4-7.  Monolayers were imaged as detailed above 
(Figure 4-13). 
 
 
Figure 4-10: Representative images demonstrating uptake of 100μg/ml pHrodo™ E. 
coli bioparticles by J774A.1 macrophages at 30minutes.   Panels show; brightfield 
image (left), fluorescent image (centre) and merged (right).  Scale bar = 50μm  
 
 
 
 
 
 
Figure 4-11: Representative images demonstrating uptake of 10μg/ml pHrodo™ E. 
coli bioparticles by J774A.1 macrophages at 30minutes.  Panels show; brightfield 
image (left), fluorescent image (centre) and merged (right).  Scale bar = 50μm  
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Figure 4-12: Time course of uptake of 10μg/ml pHrodo™ E. coli bioparticles by 
J774A.1 macrophages (merged images).  Scale bar = 50μm  
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Figure 4-13: Standard pH calibration curve generated by confocal microscopy 
measuring fluorescence of intramacrophage pHrodo™ labelled E. coli bioparticles 
against solutions of known pH 
 
4.7.4 Final method for determination of phagolysosomal pH 
Confocal microscopy was preferred as the definitive technique for determination of 
phagolysosomal pH.  This technique allowed high quality imaging, showed clear 
cellular uptake of the fluorophone therefore allowing definitive confirmation of 
intracellular fluorescence and produced little inter-assay variation. 
Images from standard fluorescent microscopy were of insufficient quality to 
generate meaningful results.  The fluorescent microplate reader technique 
exhibited large inter-assay variation, failed to demonstrate a result from the 
positive control and it could not reliably determine whether fluorescence was 
intracellular thereby leading to uncertainty over whether the data represented 
phagosomal pH.  
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4.8 Protease activity 
4.8.1 Colorimetric measurement of enzymatic action 
Protease activity was determined via enzyme-specific substrate degradation in a 
colorimetric assay according to published methodology (Liu 2012; Rivera-Marrero 
2004; Standish 2009).   
J774A.1 macrophages were seeded in triplicate into 24 well plates at 2.5x105/well 
and cultured overnight.  Monolayers were washed three times with sterile PBS, 
800μL antibiotic-free RPMI added and cells infected at a MOI of 10.  After 2h 
infection, cells were washed three times, treated with RPMI containing 20μg/ml 
gentamicin for 1h to remove extracellular bacteria, then incubated for a further 3h 
with media containing hydroxychloroquine (0-10μg/ml) or dimethylsulphoxide 
(DMSO) vehicle control.  At the end of 6h cells were washed three times with sterile 
PBS and lysed with 50mM Hepes, 50mM NaCl, 0.1% Triton X in sterile water for 
30minutes on ice.  100μL aliquots of lysate were transferred to white walled, clear 
bottom 96 well plates (Corning, Tewksbury, MA, USA) and specific substrates for 
each enzyme added: N-Succinyl-Ala-Ala-Pro-Phe p-nitroanilide (in DMSO, final 
concentration 1mM) for Cathepsin G and N-Methoxysuccinyl-Ala-Ala-Pro-Val p-
nitroanilide (in DMSO, final concentration 0.85mM) for Macrophage elastase 
(MMP12).  Plates were incubated for 24h in the dark and then OD410nm read with a 
Sunrise™ microplate reader (Tecan).   
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4.8.2 Calculation of enzymatic (protease) activity 
Enzyme activity was calculated from colourimetric enzyme specific substrate 
degradation using the Beer-Lambert equation (Wilson 2010).   
 
4.8.2.1 The Beer Lambert equation 
This states: 
 
 
 
 
 
Thus; 
 
 
Values used: 
A; change in optical density from baseline (per minute) 
ε; Cathepsin G (8800), MMP12 (132800) (Sigma-Aldrich and (Palmier 2007)) 
d; path length was calculated as detailed below 
A = Absorbance per time (change in optical density) 
ε = Molar extinction coefficient 
c = Concentration per time 
d= Path length 
A = ε x c x d 
c =      A__        
       (ε  x d) 
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4.8.2.2 Path length calculation 
The path length in a 96 well plate can be calculated by rearranging the formula for 
the volume of a cylinder 
 
 
 
 
Path length was therefore calculated using the well bottom surface area (0.32cm2) 
provided by the manufacturer (Corning) (from which r can be calculated as 3.19mm 
using area = πr2), and the filling volume (100μl). 
 
 
Therefore; 
 
So;  
 
  
h=   V_ 
       πr2 
h = Path length 
V = filling volume 
r = diameter 
h=     100μl  
       π(3.19mm)2 
h=   100mm3 
       π(3.19mm)2 
h=  100mm = 3.13mm = 0.313cm 
       31.97   
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4.8.2.3 Calculation of enzymatic activity 
Enzymatic concentration per time was therefore calculated thus: 
  
 
Finally, enzymatic units were calculated from concentration per time on the 
following basis: 
1 unit of active Cathepsin G as defined as c= 1nM/sec (Sigma) 
1 unit of MMP12 defined as c=100pM/min (Sigma) 
 
4.8.2.4 Confirmation of linear relationship between OD and enzyme activity 
This method requires a linear relationship between enzyme activity and optical 
density.  This was confirmed by co-incubating serial dilutions of purified Cathepsin 
G (0.5-20nM (Sigma-Aldrich, Dorset, UK)) and macrophage elastase (MMP12) (0.5-
2.5nM (Enzo Life sciences, Exeter, UK)) with their relevent substrates for 24h in the 
dark then optical density determined as previously detailed (Figure 4-14 and 4-15). 
concentration per time = change in OD from baseline per minute 
ε x 0.313 
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Figure 4-14: Confirmation of linear relationship between Cathepsin G enzymatic 
degradation of N-Succinyl-Ala-Ala-Pro-Phe p-nitroanilide and optical density 
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Figure 4-15: Confirmation of linear relationship between macrophage elastase 
(MMP12) enzymatic degradation of N-Methoxysuccinyl-Ala-Ala-Pro-Val p-
nitroanilide and optical density   
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4.9 Respiratory burst 
4.9.1 Flow cytometry 
A Millipore Guava® EasyCyte plus flow cytometry system (Millipore; Billerica, MA, 
USA) was used for all experiments.  
 
4.9.1.1 Measurement of intracellular respiratory burst 
Following optimisation (as described below), intracellular respiratory burst was 
measured by flow cytometry using the fluorophore Dihydrorhodamine 123 
(DHR123), fluorescent in the presence of reactive oxygen species (Emmendorffer 
1990) (Figure 4-16).  Macrophages were seeded into 24 well plates at 5x105/well, 
primed with interferon gamma (IFNγ) and cultured overnight.  Monolayers were 
washed 3 times with sterile PBS, and incubated for 3h in antibiotic-free RPMI-1640 
medium containing 20mM HEPES, and hydroxychloroquine or DMSO vehicle 
control.  Respiratory burst was initiated with either E. coli, Staph. aureus (at a 
multiplicity of infection of 100) or 1µM phorbol 12-myristate 13-acetate (PMA).  
After 15 min, 50nM DHR123 was added followed by a further 15 min incubation.  
Macrophages were then washed 3 times with sterile PBS and cells detached using 
10mM EDTA in PBS.   
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Figure 4-16: Representative flow cytometry histogram demonstrating respiratory 
burst following infection of J774A.1 macrophages with bacteria as demonstrated by 
an increase in green fluorescence (light grey) relative to uninfected controls (black).  
 
4.9.1.2 Flow cytometry data acquisition  
For each assay, gating of macrophages to exclude cellular debris was performed 
based on their scatter characteristics (Figure 4-17) and fluorescent thresholds 
adjusted as appropriate to control for background fluorescence.   A minimum of 
5000 gated events were acquired and analysed for each sample using a Guava® 
EasyCyte plus flow cytometer.    
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Figure 4-17: Representative flow cytometry scatter plot demonstrating gating of 
macrophages 
 
 
 
4.9.1.3 Optimisation of Flow cytometry 
4.9.1.3.1 Dissociation of monolayers from tissue culture plates 
In order to perform flow cytometry it was necessary to rapidly generate a single cell 
suspension of viable cells from adherent monolayers.  The EasyCyte system does 
not utilise sheath fluid, relying on capillary action to produce cell flow, meaning cell 
clumping must be avoided to prevent blockages of the flow chamber. 
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 To achieve this several solutions were tested to ensure maximum possible cellular 
yield; 
- Cell dissociation solution (Sigma) 
- Citric saline solution (15mM Sodium citrate dihydrate, 135mM Potassium 
chloride in deionised water) 
- 2mM EDTA in PBS 
- 5mM EDTA + 5mg/ml lignocaine in PBS 
- 10mM EDTA in PBS 
Trypsin was avoided due to the potential for damage to the cell surface and 
consequent effect on respiratory burst (Bryant 1986). 
Optimal dissociation of macrophages from tissue culture plates was achieved by co-
incubating monolayers with 10mM EDTA in PBS at 37oC, 95% air, 5%CO2 for 10mins 
followed by gentle pipette mixing. Light microscopy on each occasion confirmed 
near complete dissociation of monolayers. 
 
4.9.1.3.2 Confirmation and optimisation of bacterial phagocytosis 
E. coli K12 was cultured overnight on LB agar at 37oC in air, washed three times in 
PBS, adjusted to 1x109/ml in PBS, then heat killed by incubation at 60oC for 30mins 
in a water bath.  Bacteria were then labelled by first permeabilising with 1mM 
Ethyleneglycoltetraacetic acid (EGTA) pH7.4 followed by staining with the 
fluorophore Propidium iodide (PI) (120μM final concentration) for 2h at 4oC on a 
83 
 
rocking platform in the dark (Lopez-Amoros 1995).  Finally, bacteria were washed 
three times with 0.1% gelatin in HBSS, opsonised with 30% mouse serum at 37oC in 
an orbital incubator (150rpm) for 1h, washed three times with PBS and stored in 
the dark at 4oC until needed.   
Staph. aureus Oxford was stained in an identical manner with the exception of 
omitting the EGTA permeablisation step.   
E. coli XL1-blue expressing green fluorescent protein (GFP) (kindly donated by Prof. 
B. Campbell) was cultured, heat killed and opsonised as detailed above without the 
need for staining.  
Flow cytometry was undertaken as previously described and confirmed a shift in 
fluorescence consistent with phagocytosis of bacteria by macrophages (Figure 
4-18).  Assays with variable MOI demonstrated an optimal phagocytosis signal with 
an MOI of 100 (Figure 4-19). 
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Figure 4-18: Phagocytosis of green fluorescent E. coli by macrophages as 
demonstrated by flow cytometry.  Left panel shows uninfected macrophages.  Right 
panel shows green shift of macrophages infected with GFP E. coli.  Similar results 
obtained for PI labelled E. coli and S. aureus.  
 
 
 
 
 
 
Figure 4-19: The number of macrophages returning a positive signal for 
phagocytosis as demonstrated by FACS increases with MOI.  Data shown for GFP 
labelled E. coli.  Similar data obtained with PI labelled E. coli and S. aureus.  
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4.9.1.3.3 Determination of optimal DHR concentration 
Flow cytometry was performed as previously described with variable 
concentrations of DHR123.  An optimal concentration should show low levels of 
background fluorescence with a measurable increase after induction of respiratory 
burst, which in this case was determined to be 50nM of DHR 123 (Figure 4-20 and 
4-21).  
 
Figure 4-20: Optimisation of DHR123 concentration for flow cytometry. Uninfected 
macrophages showing minimal fluorescence (left panel) and infected macrophages 
showing a shift to the right (right panel, shift marked in blue) demonstrating 
intracellular respiratory burst.  In this image 50nM DHR123 was used.  
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Figure 4-21: Percentage of cells returning a positive signal for respiratory burst at 
variable concentrations of DHR 123.  Uninfected cells are shown in black and 
infected cells in grey.  50nM was optimal due to low levels of background 
fluorescence and a measurable increase after stimulation.  
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4.9.2 Chemiluminescence 
Total respiratory burst in macrophages (pre-treated with or without 
hydroxychloroquine) was measured by a microplate luminescence assay using 
lucigenin (N,N′-dimethyl-9,9′-biacridinium dinitrate).  Cells were seeded into white-
walled, clear bottom 96 well plates at 5x105/mL, primed with 100 U/ml interferon 
gamma (IFNγ) and cultured overnight.  Following three sterile PBS washes, cells 
treated with 1-10μg/ml HCQ, 20-80nM Vitamin D or vehicle control for 3h in phenol 
red-free, antibiotic-free RPMI-1640 media supplemented with 10% vol/vol FBS and 
2mM glutamine.  Lucigenin was then added to final concentration of 5µM, (a level 
at which lucigenin does not undergo redox cycling (Li, 1998)), and respiratory burst 
initiated with 1µM phorbol-12-myristate-13-acetate (PMA). Luminescence was read 
immediately using a BMG Labtech Fluostar Omega microplate reader (BMG 
Labtech; Offenburg, Germany), and subsequently every 5 min for 1h. 
4.10 Neutrophil migration assay 
Macrophage-mediated human neutrophil chemotaxis was quantified using a 
CytoSelect™ 96-Well Cell Migration Assay, 3 µm pore diameter (Cambridge 
Bioscience, Cambridge, UK) according to the manufacturer’s instructions.  
Chemotactant in the lower chamber was X-Vivo 15 medium from 105 MDMs either 
uninfected or infected for 6h with E.coli HM605 or K12 (MOI 25). CyQuant® GR 
fluorescence was measured using an F200 microplate reader (Tecan) using 
excitation at 485nm, emission detection at 535nm (Figure 4-22). 
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Figure 4-22: Schematic representation of human neutrophil migration assay.  (A) 
Medium from human macrophages either infected or uninfected with E. coli is 
placed in the bottom chamber.  (B) 2.5x105 human nuetrophils were added to the 
top chamber above a 0.3μm pore (C) Plates were incubated for 2h to allow 
migration of neutrophils through to the lower chamber with non-migratory cells 
retained in the upper chamber. (D) Migratory neutrophils were detached, lysed and 
CyQuant® GR dye added for detection  
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4.11 Cytokine release by macrophages 
Secretion of human Interleukin 6 (IL-6), Interleukin 8 (IL-8) and tissue necrosis 
factor alpha (TNFα) from MDMs in response to bacterial infection was quantified by 
sandwich ELISA as per the manufacturer’s instructions (R&D systems, Abingdon, UK 
(product codes: IL-6, D6050; IL-8, D800C; TNFα, DTA00C)) according to the 
manufacturer’s instructions. Release of murine IL-6 and TNFα in response to HCQ-
treated J774a.1 macrophages, with or without HM605 infection, was similarly 
determined by sandwich ELISA (R&D systems - product codes: IL-6, M6000B; TNFα, 
SMTA00B).  OD450nm was measured using a Sunrise™ microplate reader (Tecan).  In 
each assay standard curves were obtained to allow quantification of cytokine 
release (Figure 4-23-4-27). 
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Figure 4-23: Standard curve for murine IL-6 concentration against OD450nm 
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Figure 4-24: Standard curve for murine TNFα concentration against OD450nm 
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Figure 4-25: Standard curve for human IL-6 concentration against OD450nm 
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Figure 4-26: Standard curve for human IL-8 concentration against OD450nm 
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Figure 4-27: Standard curve for human TNFα concentration against OD450nm 
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4.12 Statistics 
N numbers indicate the total number of independent experiments performed with 
cells seeded in triplicate for each experiment unless otherwise indicated. 
Independent sample groups were assessed for normality and equality of variances. 
As appropriate, comparisons for data sets between CD and HC were analysed by 
unpaired t-test or Mann-Whitney U.  Dose responses were analysed using Cuzick’s 
test for trend, followed if significant by Dunnett’s test.  Multiple treatment groups 
were first analysed using either one-way analysis of variance (ANOVA) or a non-
parametric Kruskal-Wallis test and subsequently followed by pair-wise comparisons 
of treatment means (StatsDirect v2.6.8; Sale, UK). Differences were considered 
significant when two-tailed P<.05. 
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4.13 Human Macrophage Project Sample size calculation 
Sample size calculations were performed to take account of the potential for both 
type I and type II errors.  Type I errors occur when the null hypothesis is rejected 
when it’s true, the risk of which is determined by the critical p value (typically 
p<0.05) and is referred to as the significance level α.  Type II errors occur with 
rejection of the null hypothesis when it’s false, the probability of which is termed β.  
Statistical power is an expression of the chance of a type II error occurring and is 
defined as 1-β.  Sample size calculations were performed as per (Campbell 1995) 
and confirmed as per (Armitage 2005; Fleiss 2003) to give a 80% power at 5% 
significance.   
The number of samples in each group is given by the formula: 
 
 
 
 
 
The anticipated difference between the proportion of Crohn’s disease patients and 
controls in achieving complete killing of intramacrophage bacterial is 62.5% (Elliott 
2011).  Using the same data the mean change in intramacrophage E. coli counts 
between 1h and 4h was +394% and -65.13% for Crohn’s disease patients and 
healthy controls respectively.  However the standard deviation was not available 
n = ((Z1-α/2 + Z1-β)
2)*((Pa(1-Pa)+Pb(1-Pb)) 
δ2 
Pa = Expected proportion in group A 
Pb = Expected proportion in group B 
δ = Difference between group A and group B (i.e. Pa – Pb) 
Z1-α/2 = 1.96 (from (Campbell 1995)) 
Z1-β = 0.84 (from (Campbell 1995)) 
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meaning it was not possible to perform sample size calculations using this data.   I 
therefore estimated that a significant difference would be found if we recruited 5 
patients and 5 controls to the study, although ultimately 10 patients and 10 
controls were recruited to account for the possibility that the effect size may be 
smaller than previously reported (Table 7).  
Power (β) Significance (α) Difference (δ) Sample Size needed 
(each group) 
80% 5% 90% 1 
80% 5% 80% 2 
80% 5% 70% 4 
80% 5% 60% 5 
80% 5% 50% 6 
80% 5% 40% 8 
80% 5% 30% 12 
 
Table 7: a priori power calculation for human macrophage project.Based on 
previous studies a sample size of 5 was calculated to give 80% power at 5% 
significance.  
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5 Investigation into the ability of murine and human macrophages 
to kill Crohn’s disease mucosa-associated E. coli  
5.1 Introduction 
Genome wide association studies implicate the innate immune system in Crohn’s 
disease as a possible underlying pathogenic process, including pathways relevant to 
handling of intracellular infection.  Indeed an increase in mucosa-associated E. coli 
has been repeatedly reported in patients with Crohn’s disease, and these bacteria 
survive and replicate within macrophages leading to granuloma formation.  Further, 
functional studies demonstrate altered macrophage cytokine release and impaired 
neutrophil chemotaxis in response to both mucosal injury and subcutaneous E. coli 
injection in patients with Crohn’s disease, suggesting a failure of macrophage 
function and subsequent bacterial persistence may represent a common 
pathogenic process. 
Early studies (Mee 1980) have shown monocytes from patients with Crohn’s 
disease have a normal ability to kill Gram-positive organisms, but it is now clear that 
macrophages have specific pathways for dealing with Gram-negative organisms, 
specifically the SLAM (Signalling lymphocyte activation molecule) system (Berger 
2010), and it is therefore still possible that patients with Crohn’s disease may have a 
specific defect in the handling of Gram-negative infection.  To date no study has 
adequately addressed this and the innate ability of macrophages from patients with 
Crohn’s disease to handle Gram-negative infection remains unclear. 
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5.2 Hypothesis 
Defective macrophage killing of bacteria, particularly E. coli, may be an underlying 
pathogenic mechanism in Crohn’s disease. 
5.3 Aims 
1. To determine the ability for E. coli to survive within murine and human 
(including Crohn’s disease) macrophages 
2. To investigate patient factors which may affect the ability of human 
macrophages to kill intracellular bacteria 
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5.4 Materials and methods 
Unless otherwise stated the material and methods are as described in chapter 4.  
Thus patient recruitment is as detailed in section 4.3, and mammalian cell culture 
technique as in section 4.5. 
Comparison of baseline characteristics for healthy controls and Crohn’s disease 
patients are detailed in Figure 5-1.  Apart from a higher hsCRP level in patients with 
Crohn’s disease (mean 7.8mg /L CD, 2.2mg/L HC, P=0.03)  no significant differences 
were demonstrated between the two groups, with comparable age (mean 44.8y 
CD,  51.7y HC, P=0.297) and smoking prevalence (30% CD, 10% HC, P=0.29), 
equivalent serum Vitamin D levels (mean 26nmol/L CD, 30.8nmol/L HC, P=0.43) and 
equal prevalence of the Crohn’s disease associated SNPs tested for in this study.  No 
patients or controls were homozygote for NOD2 or IRGM variants, with one Crohn’s 
disease patient homozygote for ATG16L1 variant. 
Individual patient characteristics are summarised in Figure 5-2.  Further details are 
available in Table 10 (Appendix 1) including individual results for intramacrophage 
replication assays.  
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Figure 5-1:  Baseline characteristics of Crohn’s disease patients and healthy controls 
from whom monocyte derived macrophages were generated.  Data presented as % 
population affected or mean ± SEM as relevant. Specific SNPs analyzed were; 
NOD2/CARD15 (rs2066844, rs2066845 and rs2066847), ATG16L1 (rs2241880) and 
IRGM (rs13361189).  Abbreviations used;  hsCRP ( high-sensitivity C-reactive 
protein),  n/a ( not applicable),  wt ( wild-type).  P values as shown obtained by 
Mann-Whitney U.  
 
 
 
 
 
Healthy controls 
(N=10) 
Crohn’s disease 
(N=10) 
P value 
Male (%) 50% 20% 0.177 
Age (y) 51.7 ± 3.8 44.8 ± 5.2 0.297 
Smoker (%) 10% 30% 0.290 
Harvey Bradshaw Index n/a 5.0 ± 1.7 n/a 
Serum Vit D3 (nmol/L) 30.8 ± 4.7 26.0 ± 3.7 0.433 
hsCRP (mg/L) 2.2 ± 0.6 7.8 ± 2.0 0.03 
NOD2 homozygote w/t 90% 80% 0.556 
NOD2 heterozygote 10% 20% 0.556 
ATG16L1 homozygote w/t 40% 40% 0.999 
ATG16L1 heterozygote 60% 50% 0.677 
ATG16L1 homozygote variant 0% 10% 0.343 
IRGM homozygote w/t 80% 70% 0.628 
IRGM heterozygote 20% 30% 0.628 
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Figure 5-2: Individual characteristics of patients and healthy controls.  rs numbers 
represent specific SNPs analysed.  Abbreviations used; hsCRP (high-sensitivity C-
reactive protein), n/a ( not applicable)   
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5.5 Results 
5.5.1 Crohn’s disease associated E. coli replicate within murine macrophages 
Initial assays confirmed the previously described ability for Crohn’s disease 
associated E. coli to survive and replicate within both murine and human 
macrophages.  E. coli K12 survived within J774a.1 murine macrophages (n=3, 1.43 ± 
0.34 fold change in intracellular bacteria over 3h (mean ± SEM)) whereas Crohn’s 
disease associated E. coli HM605 and LF82 both demonstrated net replication over 
the same period (HM605; n=3, 7.00 ± 1.14, P<0.001.  LF82; 3.84 ± 0.42, n=3, 
P<0.001) (significance reported relative to K12, ANOVA) (Figure 5-3). 
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Figure 5-3:  J774a.1 murine macrophages are ineffective at killing internalised E. 
coli.  Lab reference strain K12 demonstrated intra-macrophage survival whilst 
Crohn’s disease associated E. coli (HM605 and LF82) demonstrated net replication 
(n=3, ***P<0.001, ANOVA).  
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5.5.2 Replication of intracellular bacteria within human monocyte-derived 
macrophages 
Neither Crohn’s disease nor healthy control peripheral blood MDM were very 
effective at killing E. coli.  Crohn’s disease MDM allowed net replication of 
phagocytosed E. coli HM605 (n= 10 patients, 1.08 mean fold replication over 3 
hours, 95% CI 0.39–1.78) as did healthy controls (n = 9, 1.50 mean fold replication, 
95% CI 1.02–1.97, P = 0.15, Mann–Whitney U test). Similar results were obtained 
for replication of phagocytosed E. coli K12 (CD n = 10, 0.54 mean fold replication, 
95% CI 0.24–0.84; HC, n = 10,  0.86 mean fold replication, 95% CI 0.47–1.26; P = 
0.14) and also for phagocytosed S. aureus (CD n = 10, 0.37 mean fold replication, 
95% CI 0.18–0.55; HC, n = 10, 0.48 mean fold replication, 95% CI 0.39–0.57; P = 
0.09) (Figure 5-4).  
In light of the lack of significant differences between the two study groups pooled 
results from both healthy controls and Crohn’s disease patients were analysed and 
demonstrated a small net killing effect of E. coli K12 (n=20, 0.70 fold change in 
intracellular bacteria over 3h, 95% confidence interval (CI) 0.46-0.94) and net 
replication of E. coli HM605 (n=19, 1.28 fold change, 95% CI 0.85-1.71, p<0.05 
relative to K12, 2-tailed T-test) in keeping with the phenotype of these bacteria 
observed seen within murine macrophages. 
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Figure 5-4:  MDM isolated from patients with Crohn’s disease (CD) and healthy 
controls (HC) possess similar ability to kill phagocytosed bacteria.  No significant 
differences were seen between CD and HC in the killing of E. coli HM605 (A), E. coli 
K12 (B) or Staph. aureus Oxford strain (C). Each point represents individual patient 
mean of triplicate samples, horizontal bar indicates overall mean. P values obtained 
using Mann-Whitney U test.  
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5.5.3 Effect of possession of Crohn’s disease associated NOD2 and ATG16L1 
single nucleotide polymorphisms on killing of intramacrophage E. coli 
HM605 
No correlation was seen between the total number of affected NOD2/CARD15 and 
ATG16L1 alleles and ability to kill intramacrophage HM605, but none of the patients 
with Crohn’s disease studied were homozygous for affected NOD2/CARD15 or 
IRGM alleles, and only 1 was homozygous for affected ATG16L1 (Figure 5-5).  It is 
however worthy of note that the single patient homozygous for variant ATG16L1 
had active disease and demonstrated the highest intramacrophage replication of 
HM605 (3.43 fold increase over 3h, upper empty square, right hand column, Figure 
5-5).
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Figure 5-5: Presence of NOD2/CARD15 and ATG16L1 variants were not associated 
with altered ability to kill intra-macrophage Crohn’s disease E. coli HM605. Patient 
NOD2/CARD15 and ATG16L1 status reported as number of disease associated 
alleles. Arrow indicates the single patient homozygous for variant ATG16L1 
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5.5.4 Effect of Crohn’s disease activity on killing of intramacrophage E. coli 
HM605  
There was a non-significant trend toward increased intramacrophage replication of 
HM605 among patients with Crohn’s disease with active disease (mean fold 
replication = 1.74 [95% CI, 0.67–2.81]) compared with those with inactive disease 
(mean = 0.43 [95% CI, 0.0–0.87], P = 0.10), but replication of HM605 in patients 
with active disease was similar to that seen in healthy controls (Figure 5-6).  
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Figure 5-6: Crohn’s disease activity defined by Harvey Bradshaw index did not 
significantly affect the ability of monocyte derived macrophages to kill intracellular 
Crohn’s disease associated E. coli HM605.  Each point represents individual patient 
mean of triplicate samples, horizontal bar indicates overall mean. (P=0.10, Mann-
Whitney U).  
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5.5.5 Correlation between serum highly sensitive CRP levels and killing of 
intramacrophage bacteria 
No correlation was seen between systemic inflammation, as measured by high 
sensitivity CRP (hsCRP), and the ability of monocyte derived macrophages to kill 
intracellular bacteria.   Spearman’s rank showed no correlation between hsCRP and 
killing of E. coli HM605 (rank -0.08, P=0.75, 2 tailed T-test), K12 (rank -0.35, P=0.13) 
nor Staph aureus Oxford strain (rank -0.31, P=0.19) (Figure 5-7)  
  
106 
 
0 5 10 15 20
0
1
2
3
4
r =-0.08, P =0.75
N
e
t 
re
p
lic
a
tio
n
N
e
t 
ki
lli
n
g
CD
HC
A
hsCRP (mg/L)
R
e
la
ti
v
e
 i
n
tr
a
m
a
c
ro
p
h
a
g
e
 C
F
U
a
t 
6
h
 /
 3
h
 p
o
s
t-
in
fe
c
ti
o
n
0 5 10 15 20
0
1
2
3
4
CD
HC
N
et
 r
ep
lic
at
io
n
N
et
 k
ill
in
g
r =-0.35, P =0.13
B
hsCRP (mg/L)
R
e
la
ti
v
e
 in
tr
am
ac
ro
p
h
ag
e
 C
F
U
at
 6
h
 / 
3h
 p
o
st
-i
n
fe
ct
io
n
0 5 10 15 20
0
1
2
3
4
CD
HC
N
et
 r
ep
lic
at
io
n
N
et
 k
ill
in
g
r =-0.31, P =0.18
C
hsCRP (mg/L)
R
e
la
ti
v
e
 in
tr
am
ac
ro
p
h
ag
e
 C
F
U
at
 6
h
 / 
3h
 p
o
st
-i
n
fe
ct
io
n
 
Figure 5-7:  Ability of HMDMs to kill intracellular bacteria was not associated with 
systemic inflammation as determined by hsCRP. Each point represents individual 
patient mean of triplicate samples.  r value obtained using  Spearman’s rank, P 
values obtained using Mann-Whitney U test. (A) HM605, (B) K12, (C) Staph. aureus 
Oxford strain.   
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5.5.6 Effect of smoking status on killing of intramacrophage bacteria 
Smoking status, either current, previous or never smoker, did not affect the survival 
of bacteria within monocyte-derived macrophages.   
For E. coli K12, relative change in intramacrophage bacteria over 3h in never 
smokers was 0.69 (n=7, 95% CI 0.24-1.14), in ex-smokers was 0.66 (n=9, 95% CI 
0.37-0.90) and in current smokers was 0.82 (n=4, 95% CI 0.06-1.58) (P=0.98, 
ANOVA).  Similarly for E. coli HM605, relative bacterial change in never smokers was 
1.63 (n=7, 95% CI 0.64-2.62), in ex-smokers was 1.07 (n=9, 95% CI 0.61-1.52) and in 
current smokers was 1.09 (n=4, 95% CI 0.61-1.58) (P=0.59, ANOVA).  For S. aureus 
Oxford strain, relative change in never smokers was 0.44 (n=7, 95% CI 0.30-0.58), in 
ex-smokers was 0.42 (n=9, 95% CI 0.22-0.62) and in current smokers was 0.38 (n=4, 
95% CI 0.25-0.51) (P=0.79, ANOVA) (Figure 5-8). 
 
 
Figure 5-8:  Smoking status did not affect the ability of HMDMs to kill intracellular 
bacteria.  Each point represents individual patient mean of triplicate samples, 
horizontal bar indicates overall mean.  P values obtained using ANOVA.  
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5.5.7 MDM from healthy controls and patients with Crohn’s disease have 
equivalent ability to generate neutrophil chemoattractants in response to 
E. coli infection 
E. coli infected monocyte-derived macrophages induced greater neutrophil  
chemotaxis than uninfected controls;  for K12 infected HC derived macrophages 
chemotaxis relative to uninfected controls was 223% (n=7, 95% CI 186-261%), for 
K12 infected CD derived macrophages 220% (n=10, 178-263%), for HM605 infected 
HC macrophages 265% (n=7, 95% CI 246-285%) and for HM605 infected CD 
macrophages 255% (n=10, 95% CI 231-280%)(P<0.001, ANOVA).  No significant 
differences were seen in chemotaxis induced by MDMs from healthy controls and 
Crohn’s disease patients in response to K12 infection (P=0.89, 2 tailed T-test) or 
HM605 infection (P=0.42, 2 tailed T-test) (Figure 5-9).  No significant difference was 
seen in the chemotactic response generated by MDM derived from patients with 
active CD compared with those with inactive disease (P = 0.60). 
Cytokine production in response to HM605 infection was equivalent in the two 
groups.  Mean TNFα production by MDMs for healthy controls was 1823pg/mL 
(n=7, 95% CI 1591-2056pg/mL) and for Crohn’s disease patients was 1915pg/mL 
(n=10, 95% CI 1711-2119pg/mL, P=0.27, Mann-Whitney).  Mean IL-8 release by  
healthy controls was 6639pg/mL (n=7, 95% CI 4065-9213) and by Crohn’s disease 
patients was 6644pg/mL (n=10, 95% CI 5066-8222pg/mL, P=0.89, Mann-Whitney 
U).  For IL-6 mean levels from HC was 1210pg/mL (n=7, 95% CI 711-1709pg/mL) and 
from CD was 1720pg/mL (n=10, 95% CI 1178-2262 pg/mL) (Figure 5-10). 
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Figure 5-9:  E. coli-infected MDM from patients with CD and HC have equivalent 
ability to generate neutrophil chemoattractants. MDM-induced 
neutrophil chemotaxis was equivalent between CD (N = 10) and HC (N = 7) whether 
uninfected or infected with E. coli (either AIEC HM605 orK12). Infected macrophages 
induced greater neutrophil chemotaxis than uninfected controls (P < 0.001; ANOVA).   
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Figure 5-10:  HMDM production of (A)TNF-a, (B) IL-6 and (C) IL-6 in response to 
HM605 infection were also equivalent between CD (N= 10) and HC (N= 7). All assays 
performed in triplicate. P values by Mann–Whitney U test.  
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5.6 Discussion 
The data shown here confirm the relatively poor ability of monocyte-derived 
macrophages to kill intracellular E. coli but clearly shows no significant difference 
between healthy controls and Crohn’s disease patients’ handling of 
intramacrophage bacteria.  Furthermore, both groups had an equivalent ability for 
E. coli infected MDMs to induce neutrophil chemotaxis and release 
chemoattractants, suggesting patients with Crohn’s disease do not have significant 
innate failure of macrophage function.  The ability for macrophages to kill 
intracellular bacteria was assessed relative to both clinical evidence of 
inflammation (as determined by Harvey-Bradshaw index) and serological markers 
(hsCRP), with no significant association demonstrated.  It should however be noted 
that patients with active ileal disease appear to kill E. coli least effectively and the 
patient with the single poorest clearance of intramacrophage E. coli had both active 
ileal disease and was homozygous for ATG16L1 variant (Figure 14-1, appendix 3).  
Due to small numbers in each group this finding could not be subjected to 
meaningful statistical analysis but appears to align with the more recent 
demonstration that active inflammation is required for patients with autophagy 
related polymorphisms to have a demonstrable reduction in bacterial clearance 
(Sadaghian Sadabad 2014).  Given that E. coli is perhaps more important in isolated 
ileal disease than colonic or ileocolonic Crohn’s disease (Baumgart 2007; Willing 
2009) this finding warrants further specific investigation. 
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Thus, with the probable exception of the relatively few Crohn’s disease patients 
who are homozygous for ATG16L1 polymorphisms, macrophage killing of 
phagocytosed E. coli in Crohn’s disease is generally normal. Segal and co-workers 
reported that defective neutrophil chemotaxis occurs in Crohn’s disease and 
suggest that bacteria entering the mucosa that fail to be cleared by neutrophils are 
phagocytosed by macrophages with chronic intra-macrophage replication and 
granuloma formation as a result. Although Segal et al reported that this defective 
macrophage chemotaxis was a possible result of altered chemokine production by 
macrophages(Smith 2009) the studies reported in this chapter showed no such 
defect. Other possible mechanisms for defective neutrophil chemotaxis in Crohn’s 
disease patients would include circulating inhibitors(Rhodes 1982b). 
Give the previously documented correlation between serum CRP and mesenteric 
fat CRP mRNA expression, and the ability for E. coli to induce mesenteric fat CRP 
mRNA expression, it may be postulated that higher serum CRP levels may correlate 
with differential killing of intracellular bacteria i.e. patients may demonstrate a 
raised CRP in part because of disease activity and in part due to impaired killing of 
E. coli and subsequent stimulation of mesenteric fat CRP production.  Whilst this 
study was not primarily designed to answer this question no such correlation was 
seen. 
There is clear evidence, as previously discussed, that Crohn’s disease tissue 
macrophages often contain intracellular E. coli and that in vitro this often results in 
granuloma formation. The intra-macrophage replication of E. coli is therefore a very 
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plausible therapeutic target for Crohn’s disease. This will be explored further in the 
following chapters.  
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6 Investigation into the effect of hydroxychloroquine on intra-
macrophage survival of mucosa-associated E. coli 
 
6.1 Introduction 
Occupying an intracellular niche is a recognised mechanism by which pathogens 
may escape killing by the immune system and demonstrate resistance to 
antibiotics.  Clinical conditions in which intracellular bacterial replication are key 
pathological events include Q fever (due to Coxiella burnetii), Whipple’s disease  
(due to Tropheryma whipplei) and tuberculosis (Rolain 2007).  A shared feature of 
these conditions is the adaptation of the causative organism to survive and 
replicate within the acidic environment of macrophage vesicle, a characteristic also 
shown to be true for adherent invasive E. coli (Bringer 2006). 
In both Q fever and Whipple’s disease standard antibiotic regimens are often 
ineffective even with prolonged courses and relapse is almost universal on 
cessation of treatment.  However enhanced killing of C. burnetii and T. whipplei can 
be achieved in vitro by raising the phagolysosomal pH using either chloroquine or 
hydroxychloroquine.  Clinical trials in Q fever have shown a combination of 
hydroxychloroquine and doxycycline to be effective and lead to shorter treatment 
durations and fewer relapses when compared with standard therapy (Raoult 1999). 
It might therefore be expected that hydroxychloroquine may also enhance killing of 
intra-macrophage Crohn’s disease associated E. coli and that this might be 
achievable at the typical steady state serum concentrations seen with typical oral 
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dosing regimens (1-2μg/ml) (Carmichael 2003; Munster 2002), either alone or in 
combination with antibiotics.  This is explored further in this chapter.   
6.2 Hypothesis 
Hydroxychloroquine treatment may enhance the ability of murine and human 
macrophages to kill intracellular E. coli and this effect may be synergistic with 
antibiotics 
6.3 Aims 
1. To determine the effect of hydroxychloroquine on bacterial survival in  murine 
macrophages 
2. To confirm this effect of hydroxychloroquine on bacterial survival in human 
monocyte derive macrophages 
3. To determine the direct effect of hydroxychloroquine on bacterial viability in 
culture medium 
4. To determine the effect of combining hydroxychloroquine with antibiotics on 
the survival of E. coli within murine macrophages 
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6.4 Results 
6.4.1 Hydroxychloroquine enhances killing of E. coli within murine 
macrophages 
Hydroxychloroquine induced a dose-dependent enhancement of intracellular killing 
of HM605 by J774a.1 macrophages (P< 0.001, Cuzick’s test for trend).  Net 
replication of E. coli (mean fold replication over 3 hr: 3.59 ± 0.35) occurred in the 
untreated control, but, at concentrations of HCQ ≥2 mg/mL, net killing of E. coli 
occurred.  At all concentrations tested there was a reduction in viable intracellular 
E. coli relative to vehicle control (Figure 6-1).   
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Figure 6-1:  Hydroxychloroquine (HCQ) enhances intramacrophage killing of Crohn’s 
disease associated E. coli HM605.  HCQ treatment causes a dose-dependent 
decrease in survival of intramacrophage bacteria J774A.1 murine macrophages (N 
=3, Cuzick’s test for trend P < 0.001.  ***P < 0.001 Dunnett’s test versus control).  
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6.4.2 Hydroxychloroquine enhances killing of E. coli within human monocyte 
derived macrophages 
Hydroxychloroquine also induced dose-dependent enhancement of intracellular 
killing of HM605 in human MDM (P <0.001, Cuzick’s test).  Relative to vehicle 
control bacterial survival was reduced to 26.1 ± 8.7% at 1μg/ml, to 34.1 ± 8.1% at 
2μg/ml, to 17.5 ± 11.6% at 5μg/ml and to 7.1 ± 7% at 10μg/ml(P<0.001, Dunnett’s) 
(Figure 6-2). 
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Figure 6-2:  Hydroxychloroquine (HCQ) treatment also leads to a dose-dependent 
enhancement of intramacrophage killing of Crohn’s disease associated E. coli 
HM605 in human monocyte derived macrophages. (N =5, Cuzick’s test for trend P < 
0.001.  ***P < 0.001 Dunnett’s test versus control).  
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6.4.3 Hydroxychloroquine does not directly affect bacterial viability 
Hydroxychloroquine at concentrations ranging from 1-10μg/ml showed no 
significant direct effect on growth dynamics of HM605 in broth over 7 hours as 
measured by OD600 nm.  In separate experiments hydroxychloroquine tested at the 
same concentrations had no effect on bacterial viability as determined by absolute 
colony-forming unit (CFU) count over a 6h period, nor on fold increase in CFU count 
over the same duration (Figure 6-3).  These experiments confirm that the enhanced 
killing of intramacrophage E. coli seen with hydroxychloroquine treatment (section 
6.4.1 and 6.4.2) is not a consequence of direct bactericidal action and is best 
explained by a modulation of the intracellular environment.    
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Figure 6-3:  Growth of Crohn’s disease colonic mucosa-associated E. coli HM605 in 
broth is unaffected by hydroxychloroquine.  Hydroxychloroquine (HCQ), at 
concentrations up to 10 µg/mL, had no effect on AIEC HM605 growth over 6h as 
determined by OD600 nm (A), by absolute colony forming unit (CFU) count (B) or  fold 
increase in CFU count from baseline(C)  (n=3, ANOVA).  
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6.4.4 Minimum Inhibitory Concentrations for doxycycline and ciprofloxacin 
Minimum inhibitory concentrations for doxycycline and ciprofloxacin against 
Crohn’s disease associated E. coli HM605 and LF82 were determined in a series of 
three experiments against multiple drug concentrations (range 0.002-32μg/mL in 
29 steps for ciprofloxacin and 0.016-256μg/mL in 29 steps for doxycycline) using 
Etest® gradient strips with identical results on each occasion (Figure 6-4). MIC 
results were compared to published typical maximum serum concentration 
achieved with standard oral dosing (Cmax).  These confirmed the efficacy of 
ciprofloxacin but a relative lack of action with doxycycline as shown by an MIC in 
excess of the typical Cmax. 
 
 
Figure 6-4: Results of minimum inhibitory concentration testing for doxycycline and 
ciprofloxacin against Crohn’s disease associated E. coli with reference maximum 
serum antibiotic concentrations (Cmax) after standard oral dosing as published  
  
 Cmax  
(data from literature 
with reference) 
Minimum Inhibitory 
Concentration  
HM605 
Minimum Inhibitory 
Concentration    
LF82 
Doxycycline 
(µg/ml) 
2 
(Agwuh 2006) 
3.0 6.0 
Ciprofloxacin 
(µg/ml) 
4 
(Gonzalez 1984; 
Saravolatz 2005) 
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6.4.5 Hydroxychloroquine enhances antibiotic killing of intramacrophage E. coli 
HM605  
Doxycycline at 10% Cmax was ineffective at killing intramacrophage HM605 
(89.01% ± 8.57%, mean survival relative to control ± SEM, P= 0.08, ANOVA) and only 
achieved modest decreases in viable bacteria at Cmax (75.5% ± 6.72%, P <0.01). 
However, at both 10% Cmax (48.9% ±6 5.36%, P <0.001) and Cmax (34.4% ± 4.71%, 
P< 0.001), co-treatment with hydroxychloroquine plus doxycycline led to significant 
enhancement of bacterial killing relative to control (P <0.001 at both 10% Cmax and 
Cmax; N = 6), relative to antibiotic monotherapy (P<0.001 at both 10% Cmax and 
Cmax) and was also significantly more effective than hydroxychloroquine 
monotherapy (P<0.05 at 10% Cmax, P<0.001 at Cmax) (Figure 6-5). 
Ciprofloxacin monotherapy was highly efficacious against intramacrophage HM605 
at 10% Cmax (4.95% ± 0.92%, mean survival relative to control ± SEM, N=3, 
P<0.001) and led to near complete killing at Cmax (0.2% ± 0.0%, P< 0.001).  
Hydroxychloroquine combination therapy enhanced killing of intramacrophage E. 
coli at 10% Cmax (2.8% ± 0.82%, P < 0.05 relative to antibiotic monotherapy), but 
no such effect could be demonstrated at Cmax due to the near complete killing of 
intramacrophage bacteria with antibiotic monotherapy (Figure 6-6). 
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Figure 6-5:  Hydroxychloroquine (HCQ) enhances antibiotic efficacy against 
intramacrophage E. coli. Combination therapy (antibiotic plus HCQ 1 mg/mL) was 
more effective at killing HM605 within J774.A1 macrophages than both antibiotic 
monotherapy and hydroxychloroquine monotherapy at (A) 10% Cmax 
doxycycline(Doxy) and (B) Cmax doxycyline [2mg/mL]  (n= 6, ***relative to control P 
<0.001, ### relative to monotherapy P <0.001; ANOVA ).  
123 
 
Co
nt
ro
l
HC
Q 
[1
]
Ci
pr
o 
[0
.4]
Ci
pr
o 
[0
.4[
 +
 H
CQ
 [1
]
0
50
100
*** ***
#
A
Drug [g/ml]
%
 i
n
tr
a
m
a
c
ro
p
h
a
g
e
E
.c
o
li
a
t 
6
 h
/3
 h
 p
o
s
t-
in
fe
c
ti
o
n
Co
nt
ro
l
HC
Q 
[1
]
Ci
pr
o 
[4
]
Ci
pr
o 
[4
] +
 H
CQ
 [1
]
0
50
100
*** ***
B
Drug [g/ml]
%
 i
n
tr
a
m
a
c
ro
p
h
a
g
e
E
.c
o
li
a
t 
6
 h
/3
 h
 p
o
s
t-
in
fe
c
ti
o
n
 
Figure 6-6:  Hydroxychloroquine (HCQ) also enhances ciprofloxacin (Cipro) efficacy 
against intramacrophage E. coli. Combination therapy (antibiotic plus HCQ 1 
mg/mL) was more effective at killing HM605 within J774.A1 macrophages than 
ciprofloxacin monotherapy at 10% Cmax (A) but no additional benefit was seen 
Cmax (B) [4mg/mL] (n= 3, ***P <0.001 relative to control, #P<0.05,  ANOVA ).  
 
  
124 
 
6.4.6 Hydroxychloroquine enhances antibiotic killing of intramacrophage E. coli 
LF82 
In separate experiments the effect on intramacrophage survival of E. coli LF82 after 
treatment with hydroxychloroquine plus either doxycycline or ciprofloxacin 
treatment was similar to that seen with E. coli HM605. 
Doxycycline monotherapy was similarly ineffective at 10% Cmax (80.9% ± 13.3%, 
mean survival relative to control ± SEM, N=3, P=0.17, ANOVA), whilst treatment at 
Cmax lead to a significant but incomplete reduction in intramacrophage bacterial 
survival (63.5% ± 8.4%, P<0.05, ANOVA).  Similar to the effect seen with HM605, co-
treatment with hydroxychloroquine at both 10% Cmax (66.9% ± 8.3%, P<0.05) and 
at Cmax (35.7% ± 3.3%, P<0.001) led to significant enhancement of killing of 
intracellular bacteria relative to control.  Combination treatment was more 
effective than either antibiotic or hydroxychloroquine monotherapy only at Cmax 
(P<0.01 and P<0.001 respectively) (Figure 6-7). 
Ciprofloxacin efficiently killed intramacrophage bacteria at both 10% Cmax (7.9% ± 
1.3%, mean survival relative to control ± SEM, N=3, P<0.001) and at Cmax (0.17% ± 
0.1%, P<0.001).  Co-treatment with hydroxychloroquine was more effective than 
antibiotic monotherapy at 10% Cmax (P<0.05) but no effect could be demonstrated 
at Cmax due to the very low bacterial survival (Figure 6-8). 
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Figure 6-7:   Hydroxychloroquine (HCQ) and doxycycline (Doxy) combination therapy 
was significantly more effective than either hydroxychloroquine or antibiotic 
monotherapy in killing intramacrophage E. coli LF82 at 10% Cmax (A) and at Cmax 
(B).  (n=3, * P<0.05 *** P<0.001 relative to control, ##P<0.01 ,###P<0.001,  ANOVA)  
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Figure 6-8:  Hydroxychloroquine (HCQ) and ciprofloxacin (Cipro) combination 
therapy was also significantly more effective than either hydroxychloroquine or 
antibiotic monotherapy in killing intramacrophage E. coli LF82 at 10% Cmax (A) but 
no additional benefit was seen at Cmax (B).  (n=3, # P<0.05, *** P<0.001; ANOVA)  
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6.5 Discussion 
The data shown in this chapter demonstrate the ability of hydroxychloroquine to 
enhance killing of intracellular Crohn’s disease-associated E. coli in both human and 
murine macrophages.  Further, hydroxychloroquine enhances antimicrobial activity 
and these effects are independent of any direct bactericidal action.  
Hydroxychloroquine undergoes steady-state pharmacokinetics but with significant 
variation in time to steady-state dependent on dosing regimen.  Typical oral dosing 
(400-800mg/day) typically achieves stable serum levels of 1-2μg/ml by 5-10 weeks 
(Munster 2002).  The data here shows enhanced killing at levels achievable with 
standard oral dosing.   
It is notable that in Whipple’s disease continued hydroxychloroquine mono-therapy 
at these concentrations after initial induction therapy with antibiotics, allows 
withdrawal of antibiotic therapy without allowing bacterial re-growth (Boulos 
2004).  Given the enhanced killing of intramacrophage E. coli seen shown here with 
combination antibiotics and hydroxychloroquine, a strategy of dual treatment 
during induction followed by period of maintenance single agent 
hydroxychloroquine therapy may allow clearance of Crohn’s disease associated E. 
coli without the risks associated with long term antibiotic use. 
One of the key concerns surrounding the therapeutic use of hydroxychloroquine is 
the reported risk of ocular toxicity.  However the actual incidence of retinopathy is 
low and previous case series have reported no toxicity in patients treated for less 
than 6 years (Levy 1997; Mavrikakis 2003).  These data suggest hydroxychloroquine 
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as an adjunct to antibiotics may represent a useful therapeutic option in Crohn’s 
disease.  
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7 Investigation into the mechanisms by which hydroxychloroquine 
affects intra-macrophage E. coli  survival 
7.1 Introduction 
Despite its established use in the treatment of specific infections few data exist to 
explain the antibacterial effect of hydroxychloroquine, with most published 
literature extrapolated from studies using chloroquine.  Key proposed mechanisms 
include effects of the availability of intracellular iron (Byrd 1991; Fortier 1995) and 
alterations in lysosomal pH (Poole 1981) – both will be explored in this chapter. 
Respiratory burst, via phosphatidylinositol-3-phosphate (PI(3)P)-dependent 
activation of NADPH-oxidase (nicotinamide adenine dinucleotide phosphate-
oxidase), is known to have relevance in the killing of intra-macrophage E. coli 
(Berger 2010) , and may be affected by hydroxychloroquine treatment (Styrt 1986).   
The optimal pH for serine protease activity is normally alkaline and in the case of 
Cathepsin G is 7.5 and for Macrophage elastase is 8.0 (Korkmaz 2010).  We 
anticipate that hydroxychloroquine treatment may increase phagolysosomal pH 
towards the optimal environment for protease activity and thereby enhance 
protease killing of AIEC.  The effect on cytokine production will also be explored 
since this has also been implicated (Jeong 1997).    
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7.2 Hypothesis 
Hydroxychloroquine may lead to enhanced killing of intracellular bacteria by 
favourably altering the intracellular environment 
7.3 Aims 
1. To determine the effect of intracellular iron availability on the ability of 
hydroxychloroquine to enhance macrophage killing of E. coli 
2. To determine the effect of hydroxychloroquine on phagolysosomal pH 
3. To determine the effect of hydroxychloroquine on respiratory burst, protease 
function and cytokine release 
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7.4 Results 
7.4.1 Iron treatment only partially antagonises the effect of 
hydroxychloroquine on bacterial survival 
Data extrapolated from studies using chloroquine suggests the effect of 
hydroxychloroquine on bacterial survival may arise due to pH dependent alteration 
in the availability of intracellular iron i.e. phagolysosomal pH rises but may not be 
directly bactericidal, but may be sufficient to reduce bacterial survival by limiting 
availability of iron.  To assess this E. coli infected macrophages were co-treated with 
hydroxychloroquine and ferric citrate (which allows pH-dependent release of ferric 
iron and thus should not reverse the effect of hydroxychloroquine on bacterial 
survival if the mechanism is pH-dependent alteration in iron availability) and FeNTA 
(allowing release of ferric iron irrespective of pH and which should, if pH-dependent 
alterations in iron are the key mechanism, therefore fully prevent the reduction in 
intra-macrophage bacterial survival observed with hydroxychloroquine treatment). 
Only a limited effect was observed with only a partial reversal of the effect of 
hydroxychloroquine seen, and only at doses of 5 to 10 μg/mL HCQ.  
Supplementation with a pH-dependent iron compound had a statistically significant 
greater impact on hydroxychloroquine induced reduction in bacterial survival.  At 
5μg/ml bacterial survival was 11.8 ± 2.2% with HCQ, 31.0 ± 6.2% with FeCit 
(P=0.003 relative to monotherapy, ANOVA) and 25.5 ± 5.5% with FeNTA (P<0.05, 
ANOVA).  At 10μg/ml bacterial survival was 3.0 ± 0.8% with HCQ, 8.5 ± 0.9% with 
FeCit (P<0.001 relative to monotherapy, ANOVA) and 6.6 ± 0.6% with FeNTA 
(P=0.003, ANOVA) (Figure 7-1).   
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Figure 7-1:  Iron supplementation only partially antagonizes the effect of 
hydroxychloroquine (HCQ) on intracellular survival of E. coli HM605 in J774A.1 
macrophages, with effects only seen a higher concentrations of HCQ.  Significance 
reported relative to hydroxychloroquine monotherapy at any given HCQ 
concentration (N= 3; *P<0.05, **P <0.01, ***P< 0.001, ANOVA).  
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7.4.2 Hydroxychloroquine increases phagolysosomal pH 
Addition of HCQ to E. coli HM605-infected J774A.1 macrophages caused a dose-
dependent increase in phagolysosomal pH (n = 6, P < 0.005, Cuzick’s test for trend).  
From a baseline of 5.21 ± 0.31 (mean ± SEM), pH increased stepwise to 5.38 ± 0.32 
at HCQ 1μg/mL, 5.55 ± 0.31 at HCQ 2μg/mL, 5.56 ± 0.36 at HCQ 5 μg/mL and 7.25 ± 
0.47 at 10 μg/mL (Figure 7-2 and 7-3).  Time-course experiments demonstrated the 
onset of pH change occurred within 30minutes, as shown in (Figure 7-2). 
 
Figure 7-2: Confocal images illustrating increased phagolysosomal pH with 
hydroxychloroquine (HCQ) as indicated by decreased pHrodo™ fluorescence 
compared with untreated control. The numbers indicate the concentration of 
hydroxychloroquine in μg/ml (e.g. HCQ 1 = 1μg/ml).  Onset of the change in pH 
occurs within 30 minutes (bottom right panel).  
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Figure 7-3:  Hydroxychloroquine increased phagolysosomal pH in E. coli HM605-
infected J774A.1 macrophages as quantified by confocal microscopy measured 
pHrodo™ fluorescence (n= 6,Cuzick’s test for trend P <0.005, **P< 0.01 Dunnett’s 
test versus control)  
 
7.4.3 Hydroxychloroquine treatment of J774a.1 murine macrophages has 
limited effect on respiratory burst 
Phorbol-12-myristate-13-acetate (PMA) induced total respiratory burst in 
interferon gamma (IFNγ) primed J774a.1 murine macrophages as determined by 
relative increase in lucigenin-mediated luminescence relative to unstimulated 
control was unaffected by treatment with hydroxychloroquine at any of the 
concentrations tested (n=5, P=0.73, Cuzick’s test for trend) (Figure 7-4). 
There was a significant trend towards reduced intracellular respiratory burst as 
determined by flow cytometric measurement of dihydrorhodamine fluorescence 
(n=5, P<0.05, Cuzick’s) although none of the tested concentrations reached 
significance against control (ANOVA) (Figure 7-5). 
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Figure 7-4:  Hydroxychloroquine treatment of J774a.1 murine macrophages did not 
affect total respiratory burst as determined by lucigenin-mediated luminescence  
(n=5, Cuzick’s test for trend, P=0.73)  
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Figure 7-5:  Hydroxychloroquine treatment of J774a.1 murine macrophages led to a 
trend towards reduced intracellular respiratory burst as determined by flow 
cytometry  (n=5, Cuzick’s test for trend P<0.05, relative to control P=0.26, ANOVA)  
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7.4.4 Hydroxychloroquine increases Cathepsin G and macrophage elastase 
activity 
Cathepsin G activity in whole cell lysates of J774a.1 murine macrophages was 
significantly higher in E. coli K12 infected cells (3.11 ± 0.3 units, mean ± SEM) than 
in either uninfected (2.23 ± 0.2 unit, n=4, P<0.05, ANOVA) or E. coli HM605 infected 
cells (2.03 ± 0.2) (P<0.05, ANOVA) (Figure 7-6).  
Baseline macrophage elastase (MMP12) activity in uninfected cells was 777.8 ± 70.6 
units (mean ± SEM) and was unaffected by infection with either E. coli HM605 
(814.0 ± 69.0 units) or E. coli K12 (902.0 ± 71.4 units) (n=4, P=0.44, ANOVA) (Figure 
7-7). 
A subtle but statistically significant trend to increased Cathepsin G activity was seen 
in HM605 infected murine macrophages following treatment with 
hydroxychloroquine, rising from a baseline of 2.03 ± 0.23 units (mean ± SEM) to 
2.78 ± 0.2 units with HCQ 10μg/mL (n=4, P=0.03, Cuzick’s) (Figure 7-8). 
Similarly, a modest increase in macrophage elastase activity was observed in 
HM605 infected macrophages treated with hydroxychloroquine, rising from a 
baseline of 814.0 ± 69.0 units (mean ± SEM) to 1089.0 ± 75.8 units with HCQ 
10μg/mL (n=4,  P<0.05, Cuzick’s) (Figure 7-9). 
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Figure 7-6:  Cathepsin G activity in whole cell lysates of murine macrophages is 
increased by infection with E. coli K12, but not HM605, relative to uninfected 
controls  (n=4, *P<0.05, #P<0.05, Bonferroni) .  
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Figure 7-7:  MMP12 activity in whole cell lysates of murine macrophages is 
unaffected by infection with E. coli relative to uninfected controls  (n=4, P=0.44, 
ANOVA).  
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Figure 7-8:  Hydroxychloroquine increases Cathepsin G activity in whole cell lysates 
of HM605 infected J774A.1 murine macrophages  (n=4, P=0.03; Cuzick’s test for 
trend)  
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Figure 7-9:  Hydroxychloroquine increases MMP12 activity in whole cell lysates of 
HM605 infected J774A.1 murine macrophages (n=4, P=0.04 Cuzick’s; *P<0.05 
Dunnett’s test).  
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7.4.5 Hydroxychloroquine does not affect murine macrophage cytokine release 
Mean TNFα release from E. coli HM605 infected J774a.1 murine macrophages was 
511.7 ± 78.8pg/mL (mean ± SEM).  Hydroxychloroquine treatment did not lead to 
any significant difference in TNFα production relative to vehicle treated control 
(n=3, P=0.31, Cuzick’s) (Figure 7-10). 
Similarly E.coli HM605 generated IL-6 release to a mean concentration ± SEM of 
246.9 ± 41.7 pg/mL.  Again this was unaffected by co-treatment with 
hydroxychloroquine relative to vehicle control (n=3, P=0.79, Cuzick’s) (Figure 7-11). 
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Figure 7-10:  Hydroxychloroquine (HCQ) did not induce significant TNFα release in 
the absence of infection, nor alter production in Crohn’s disease colonic mucosa-
associated E.coli HM605 infected J774A.1 murine macrophages  (n=3, P=0.31, 
Cuzick’s test for trend).   
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Figure 7-11:  Hydroxychloroquine (HCQ) did not induce significant IL-6 release in the 
absence of infection, nor alter production in Crohn’s disease colonic mucosa-
associated E.coli HM605 infected J774A.1 murine macrophages  (n=3, P=0.79, 
Cuzick’s test for trend).  
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7.5 Discussion 
These data confirm data extrapolated from experiments using chloroquine and for 
the first time demonstrate a significant effect of hydroxychloroquine treatment on 
phagolysosomal pH.  Relative to untreated control this effect on pH only reached 
significance at the highest concentration tested but the fact that alterations in 
bacterial survival can be demonstrated at lower concentrations of 
hydroxychloroquine is almost certainly a reflection of the technically challenging 
nature of phagolysosomal pH measurement and a lack of sensitivity of the assay in 
demonstrating subtle pH change.  It seems probable that these subtle pH changes 
are sufficient to alter bacterial survival but that the magnitude of pH change is 
insufficient for individual doses to reach significance relative to control.  This is 
supported by the analysis of the data set as a whole when a statistically significant 
trend was demonstrated across all concentrations by Cuzick’s test.   
A modest role was seen for alterations in iron metabolism and hydroxychloroquine 
had little effect on respiratory burst, protease activity and cytokine release.   
Hydroxychloroquine has been used to successfully treat chronic granulomatous 
disease (CGD), a condition where defective NADPH oxidase function is a central 
feature and in which a Crohn’s disease like colitis is common (Arlet 2008).  It might 
therefore have been expected that an increase in respiratory burst would have 
been seen with hydroxychloroquine treatment but these data show a negligible and 
negative effect.  It should however be noted that the mechanism of action in GCD 
has not been elucidated and it remains possible that alterations in bacterial survival 
underpin efficacy in keeping with the data shown here. 
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Following internalisation bacteria are normally processed through the macrophage 
phagosomal pathway  leading to the ultimate formation of the acidic mature 
phagolysosome - in the context of E. coli infection phagosomal pH has been 
reported to rapidly fall to around 5 (Berger 2010).  Crohn’s disease associated E. coli 
demonstrate resistance to this acidification, a recognised mechanism by which 
bacterial avoid killing (Flannagan 2009), to preferentially replicate within the acidic 
mature phagolysosome (Bringer 2006; Subramanian 2008).  Manipulation of 
compartmental pH is has been previously shown to achieve clinically relevant 
enhancement of C. burnetii and T. whipplei killing (Fenollar 2014; Maurin 1992) and 
these data suggest the rise in pH seen following treatment is the predominant 
mechanism through which hydroxychloroquine exerts its effect on intra-
macrophage bacterial survival. 
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8 Investigation into the effect of Vitamin D on intra-macrophage 
survival of mucosa-associated E. coli 
8.1 Introduction 
In the last decade huge interest has surrounded the role of Vitamin D in the 
immune system.  Vitamin D modulates monocyte function (Nelson 2011), is 
required for adequate antimicrobial peptide secretion from human macrophages 
(Fabri 2011), stimulates NOD2 expression and thereby defensin production (Wang 
2010), and also affects T-cell function (Hewison 2012).  In light of the growing 
evidence for a role in both innate and adaptive immunity the definition of adequate 
serum levels has been frequently debated and revised, with current evidence and 
consensus now defining deficiency as <20nM (Hewison 2012; Rosen 2011) and 
>80nM as sufficient for optimal immune cell function (>80nM) (Alappat 2010; Fabri 
2011; Hewison 2012).   
Vitamin D deficiency is common in Crohn’s disease, active disease is associated with 
lower serum levels (Jorgensen 2013), polymorphisms in the vitamin D receptor are 
associated with a risk of developing Crohn’s disease (Simmons 2000) and conversely 
higher predicted levels are associated with a reduced risk of disease development 
(Ananthakrishnan 2012). 
In animal models of a spontaneous inflammatory bowel disease like illness, 
knockout mice supplemented with vitamin D are prevented from developing 
disease (Cantorna 2000).  In humans supplementation reduces the risk of needing 
IBD –related surgery, non-significantly reduces the risk of clinical relapse and is 
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associated with a reduced requirement for healthcare (Ananthakrishnan 2013a; 
Jorgensen 2010; Kabbani 2016). 
8.2 Hypothesis 
Vitamin D supplementation may enhance the ability of macrophages to kill 
intracellular bacteria 
8.3 Aims 
1. To determine the effects of Vitamin D supplementation on intramacrophage 
bacterial survival 
2. To determine the effect of Vitamin D supplementation on respiratory burst 
3. To assess the relationship between serum Vitamin D concentration and the 
ability of human monocyte derived macrophages to kill intracellular bacteria 
  
145 
 
8.3.1 Vitamin D enhances killing of E. coli HM605 within murine macrophages 
1, 25-dihydroxyvitamin D3 treatment led to a dose-dependent reduction in survival 
of E. coli HM605 within J774a.1 murine macrophages relative to vehicle treated 
control (n=3, P< 0.001, Cuzick’s test for trend).  In the absence of vitamin D 
supplementation HM605 replicated 6.45 ± 0.53 fold over 3h.  A relative reduction in 
bacterial survival was seen at 20nM vitamin D, with net killing seen at 80nM, and 
both concentrations reaching significance relative to control (n=3, P<0.001, 
Dunnett’s) (Figure 8-1). 
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Figure 8-1:  Vitamin D enhances intramacrophage killing of E. coli HM605. 1,25 OH2-
vitamin D3 caused dose-dependent decrease in intramacrophage survival of HM605 
in J774A.1 murine macrophages  (N =3, P< 0.001 Cuzick’s test for trend, ***P< 0.001 
Dunnett’s test versus control.)  
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8.3.2 Vitamin D supplementation enhances E. coli killing by human monocyte-
derived macrophages  
Similarly, vitamin D supplementation significantly decreased intramacrophage 
survival of E. coli HM605 within human monocyte-derived macrophages in a dose-
dependent manner (n=3, P=0.012 Cuzick’s test for trend).  When considering 
individual doses relative to vehicle-treated control, only 80nM reached significance 
(n=3, P<0.05, Dunnett’s) (Figure 8-2). 
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Figure 8-2:  1,25 OH2-vitamin D3 also led to a dose-dependent decrease in 
intramacrophage survival of HM605 in human MDM  (N=3, P=0.012 Cuzick’s test for 
trend, *P< 0.05 Dunnett’s test versus control).  
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8.3.3 Vitamin D treatment of murine macrophages increases intracellular 
respiratory burst but does not affect total respiratory burst 
Phorbol-12-myristate-13-acetate (PMA) induced intracellular respiratory burst in 
interferon gamma (IFNγ) primed J774a.1 murine macrophages as determined by 
flow cytometric quantification of dihydrorhodamine fluorescence was increased by 
treatment with vitamin D (n=5, P<0.01, Cuzick’s).  Relative to vehicle treated control 
only treatment with 80nM vitamin D significantly increased intracellular respiratory 
burst (n=5, P<0.05, Dunnett’s) (Figure 8-3). 
No significant effect on total respiratory burst as determined by lucigenin mediated 
luminescence was demonstrated (n=5, P=0.39, Cuzick’s) (Figure 8-4). 
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Figure 8-3:  Treatment of J774a.1 murine macrophages with 1,25OH2Vitamin D3 
increased intracellular respiratory burst as determined by flow cytometry  (n=5, 
Cuzick’s test for trend P<0.01, *P<0.05, Dunnett’s test versus control)   
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Figure 8-4:  Treatment of J774a.1 murine macrophages with 1,25OH2Vitamin D3 did 
not affect total respiratory burst as determined by lucigenin mediated luminescence  
(n=5, Cuzick’s test for trend,  P=0.39).  
 
  
8.3.4 The ability of human MDM to kill intracellular bacteria was not correlated 
with serum vitamin D levels 
Serum vitamin D levels, as quantified by the Royal Liverpool University Teaching 
Hospital Biochemistry Department from serum samples obtained from patients and 
healthy volunteers, did not correlate with the ability of MDMs to kill intracellular 
bacteria.  Given the lack of difference between the ability of MDMs derived from 
healthy controls and patients with Crohn’s disease to kill intracellular bacteria, all 
samples were pooled for analysis.  Spearman’s rank coefficient for E. coli HM605 
was 0.051 (n=20, P=0.84, Mann-Whitney U), for E. coli K12 was 0.07 (P=0.79) and 
for Staph aureus Oxford strain was 0.10 (P=0.68) (Figure 8-5). 
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Figure 8-5:  Ability of HMDMs to kill intracellular bacteria was not correlated with 
serum Vitamin D levels. Each point represents individual patient mean of triplicate 
samples.  r value obtained using  Spearman’s rank, P values obtained using Mann-
Whitney U test. (A) HM605, (B) K12, (C) Staph. aureus Oxford strain.   
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8.4 Discussion 
A clear enhancement of the ability of macrophages, both human and murine, to kill 
intracellular bacteria was seen with vitamin D supplementation, largely 
independent of effects on respiratory burst.  These data did not have sufficient 
power to assess whether the relative benefit of vitamin D supplementation on 
bacterial killing is influenced by the concentration in circulating donor serum but no 
correlation was seen between serum vitamin D levels and killing of intracellular 
bacteria in the absence of supplemental treatment.   
Additional studies to determine to what extent baseline vitamin D levels affect the 
response to supplementation would be appropriate to explore this further, as 
would an assessment of the effect on tissue concentrations (rather than serum 
levels) and their correlation with macrophage function.  It seems probable from the 
data here that an increase in the vitamin D concentration in the macrophage micro-
environment enhances their anti-microbial activity. 
In patients with deficiency (<20nM (<8ng/mL)) or insufficiency (20-75nM (8-
30ng/mL)) a normal serum concentration of 75-80nM or greater (30-32ng/mL) can 
be be achieved with oral replacement therapy including, in some cases, over the 
counter preparations.  Beneficial effects on serum vitamin D levels can be achieved 
with Cholecalciferol 400-1000 IU/day but this will commonly fail to achieve optimal 
levels, particularly in patients with small bowel disease where doses may need to 
be doubled.  Dependent on baseline concentrations, doses of 5000 IU/day are 
commonly required and up to 10,000 IU/day considered safe (Hlavaty 2015).  In 
light of the data shown here and the building evidence for positive effects both on 
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immune cell function and the clinical course of Crohn’s disease it would now seem 
appropriate to screen all patients for deficiency on a routine basis, akin to the 
practice of checking B12, folate and iron levels.  It might be argued that because the 
randomised trial of supplementation failed to reach significance more data is 
required before translation into clinical practice but in the context of a 
demonstrable vitamin deficiency withholding replacement may be hard to justify 
and a trial set up to investigate this in the USA (ClinicalTrials.gov NCT02208310) 
closed because of futility, presumably because vitamin deficient patients were 
unwilling to receive placebo. 
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9 Summary  
 
 Crohn’s disease associated E. coli survive and replicate in macrophages 
 Peripheral blood monocyte derived macrophages from patients with Crohn’s 
disease and healthy controls have equivalent ability to kill intracellular bacteria 
with the exception of a patient homozygous for variant ATG16L1 
 Monocyte- derived macrophages from Crohn’s disease patients had a normal 
ability to generate neutrophil chemotaxis and chemotactic cytokines in vitro  
 Hydroxychloroquine enhances macrophage killing of intracellular E. coli in a 
dose-dependent manner 
 Hydroxychloroquine enhances antibiotic killing of intra-macrophage E. coli 
 Hydroxychloroquine increases phagolysosomal pH and in addition has subtle 
effects on intracellular iron metabolism and protease activity 
 Vitamin D supplementation enhances intramacrophage killing of E. coli but 
macrophage bactericidal function is not correlated with serum Vitamin D 
concentrations  
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10 Discussion and implications for future studies 
The data shown here demonstrates relatively poor killing of intracellular Crohn’s 
disease associated E. coli by human monocyte-derived macrophages derived from 
both healthy controls and patients with Crohn’s disease and without any significant 
differences between the two groups.   
The presence of circulating bacterial DNA in the blood of patients with Crohn’s 
disease has been consistently reported, with some studies demonstrating 
universally positive results in Crohn’s disease patients, and most studies 
demonstrating higher rates in patients with active disease relative to quiescence  
(Gutierrez 2014; Vrakas 2017).  Bacterial translocation occurs across M-cells, is 
increased by environmental factors including emulsifiers commonly found in 
western foods, is associated with NOD2 and ATG16L1 variants and correlates with a 
more aggressive disease course including a greater need for biological treatment 
and a higher risk of post-operative complications (Gutierrez 2014; Li 2015; Roberts 
2010).   
Following translocation, bacteria are ineffectively cleared from tissues and defects 
in neutrophil chemotaxis to the site of injury or inflammation have been 
consistently reported in patients with Crohn’s disease with altered macrophage 
chemokine secretion suggested as a mechanism (Smith 2009).  The data shown 
here suggests the previously observed failure of chemokine secretion, also variably 
reported elsewhere in response to MDP, cantharidin skin blisters and mucosal 
injury (Harbord 2006; Marks 2006; Sewell 2012), may arise not as a consequence of 
an inherent macrophage defect as previously postulated but perhaps arises in situ 
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following local inhibition of otherwise normal macrophages.  It has already been 
shown that microbial mannan possess the ability to inhibit macrophage function 
(Mpofu 2007) and it is noteworthy that older studies have previously demonstrated 
circulating factors can  inhibit neutrophil chemotaxis (D'Amelio 1985; Rhodes 
1982b). 
These data support the targeting of intra-macrophage E. coli as a therapeutic 
strategy.  Data reported here clearly show enhancement of macrophage killing of E. 
coli by hydroxychloroquine, and that hydroxychloroquine acts synergistically with 
antibiotics to improve bacterial clearance.   
In diseases where intramacrophage bacterial survival is central to pathogenesis, 
hydroxychloroquine in combination with antibiotics has become standard 
treatment.  In Q fever a clinical trial of treatment with hydroxychloroquine and 
doxycycline targeted at the causative agent, Coxiella burnetii, was superior to 
standard therapy, shortened treatment duration and reduced the risk of relapse 
(Raoult 1999).  Similar results are achieved in Whipple’s disease where Tropheryma 
whipplei is effectively cleared from infected MRC5 cells by hydroxychloroquine and 
doxycycline combination (Boulos 2004).  Due to the rarity of Whipple’s disease a 
clinical trial has not been possible but this approach has now been adopted as 
standard treatment (Fenollar 2014). 
Clinical data for the use of hydroxychloroquine as a treatment for IBD is currently 
lacking although in ulcerative colitis it prevents experimental colitis in rabbits 
(Rhodes 1982a) and chloroquine treatment has been shown to have similar short 
term efficacy to sulfasalazine (Goenka 1996).  Hints towards potential efficacy in 
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Crohn’s disease are given by clinical studies in both sarcoidosis and chronic 
granulomatous disease where is has been successfully used to treat granulomatous 
manifestations of the diseases (Arlet 2008; Doherty 2008).  To date only one 
published study of only four patients exists for the use of hydroxychloroquine in 
Crohn’s disease where hydroxychloroquine treatment failed to show a benefit of in 
the prevention of post-operative recurrence, although the very small numbers 
make it impossible to draw any firm conclusions regarding efficacy (Louis 1995).  A 
clinical trial is therefore needed and based on this study such a trial is now 
recruiting, with a significant contribution to protocol development made by this 
author.  The pilot open label trial will compare the efficacy of combination 
hydroxychloroquine, ciprofloxacin and doxycycline with budesonide in the 
treatment of active Crohn’s disease (EudraCT Number: 2008-001137-99).  Primary 
end points are remission at 10 weeks, remission at 24 weeks and remission at 52 
weeks as defined by Crohn’s disease activity index (CDAI) ≤150.  Secondary end 
points include remission at 4 weeks, response at 10 weeks (fall in CDAI of >70 
points), quality of life, tolerability and fall in faecal calprotectin. 
Given the potential role for defective autophagy in the pathogenesis of Crohn’s 
disease it might be argued that hydroxychloroquine, which can inhibit autophagy by 
blocking fusion of lysosomes and phagosomes, may represent a counterintuitive 
treatment (Rabinowitz 2010).  It is however important to recognise that Crohn’s 
disease associated E. coli typically escape autophagic pathways even in healthy 
phagocytes (Lapaquette 2012).  Further, the effect on autophagy is a dose-
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dependent phenomenon, and at low doses treatment may actually enhance 
endosome fusion (Bhat 2000).  
Whilst primary macrophage dysfunction seems unlikely in the majority of patients 
with Crohn’s disease the finding of poor killing by macrophages from a single 
patient homozygous for ATG16L1 is notable and is comparable to findings reported 
by other groups since this study completed  (Vazeille 2015).  It has been shown that 
experimental inhibition of autophagy favours intracellular survival of Crohn’s 
disease associated E. coli (Lapaquette 2012) suggesting a functional consequence of 
genetic polymorphisms may be relevant.  However conflicting data are given by two 
further studies, only one of which addressed killing of E. coli (Elliott 2015; Glubb 
2011), and whilst responses to MDP stimulation are attenuated by genetic variation 
this does not translate into a change in handling of intra-macrophage gram-
negative infection (Homer 2010).  This disparity may be explained by the finding 
that in patients homozygous for ATG16L1 alterations in the ileal microbiome and 
impairment of monocyte killing of Crohn’s disease mucosa-associated E. coli are 
only seen in the presence of inflammation (Sadaghian Sadabad 2014).  It is 
noteworthy that in the study presented here there was a non-significant trend 
towards inferior killing in patients with active Crohn’s disease, albeit in a mixed 
genetic population, raising the possibility that variation in macrophage function 
may also arise as a consequence of inflammation rather than as a primary 
phenomenon.  Using a non-selective recruitment policy in populations with minor 
allele frequencies of 1-4% (NOD2), 9% (IRGM) and 53% (ATG16L1) (Ellinghaus 2016; 
Jostins 2012), a sufficiently powered study would need to be far larger than has 
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been possible here in order to fully explore the interplay of genetic variation, 
inflammation and macrophage function.   Further studies are therefore indicated to 
undertake a targeted comparison of macrophage function in patients already 
known to possess autophagy-related polymorphisms and to better understand the 
impact of inflammation.   
Vitamin D is required for interferon-dependent macrophage function, stimulates 
NOD2 expression, induces autophagy and increases defensin production (Fabri 
2011; Wang 2010; Yuk 2009).  The data here show a clear benefit from in vitro 
vitamin D supplementation in the ability of macrophages to kill internalised E. coli.  
These data further support the use of vitamin D replacement in patients with 
Crohn’s disease.   Given that several published studies have demonstrated benefits 
from replacement therapy including a reduced risk of needing surgery, lower 
requirement for healthcare, a reduced risk of disease progression, and the ability to 
prevent disease in knockout mouse models, a test and treat policy appears 
justifiable for vitamin D, particularly as a fully powered placebo-controlled clinical 
trial is unlikely to be realised (Ananthakrishnan 2013a; Cantorna 2000; Kabbani 
2016).  Further studies to look at the impact of vitamin D treatment on autophagic 
pathways would be of interest, as would a prospective investigation considering the 
correlation between serum concentrations, disease activity and circulating markers 
of E. coli infection and how this might alter following supplementation. 
Comparable to previous studies the data here shows effective clearance of Gram-
positive infection by macrophages from both Crohn’s disease patients and healthy 
controls (Mee 1980).  It is however important to note that macrophages possess 
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specific pathways for handling of intracellular Gram-negative bacteria, specifically 
involving signalling lymphocytic activation molecule F1 (SLAMF1 or CD150 or 
commonly simply SLAM), and the relevance of this is unknown in Crohn’s disease.  
One previous very small study demonstrated abundant SLAM positive cells in ileal 
resection specimens taken from patients with Crohn’s disease but the functional 
significance has not been addressed to date (Theil 2005).  SLAM has several roles 
including stimulation of Th2 cytokine secretion, natural killer cell development and 
acts a measles virus receptor.  It has been shown SLAM acts as a microbial sensor 
where, following interaction with outer-membrane protein C (ompC) expressed by 
E. coli, SLAM is internalised along with E. coli and results in phosphatidylinositol-3-
phosphate (PI(3)P)-dependent activation of NADPH oxidase and hence bacterial 
killing (Berger 2010).   SLAMF2 (CD48) also acts as a receptor for FimH expressed by 
E. coli and this may also be of relevance.  Future studies should consider the role of 
SLAM and whether this is relevant to the failed clearance of E. coli. 
The present studies were based on peripheral blood monocyte-derived 
macrophages.  It would be very interesting but technically much more difficult to 
assess the function of Crohn’s disease and control tissue macrophages. Any such 
future study may wish to combine the approach taken here with molecular 
pathway analysis of tissue macrophages obtained by fluorescence-activated cell 
sorting. 
In conclusion this study found no demonstrable difference in killing of intracellular 
bacteria by macrophages from patients with Crohn’s disease, reaffirms the ability of 
Crohn’s disease associated E. coli to survive and replicate within macrophages and 
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demonstrates a role for hydroxychloroquine, in combination with antibiotics, and 
vitamin D supplementation to enhance macrophage killing of E. coli.  These findings 
are being further assessed in an ongoing clinical trial.  
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12 Appendix 1 
12.1 Monocyte derived macrophage study:  Inclusion/exclusion criteria  
 
Table 8: Inclusion and exclusion criteria for recruitment to the human macrophage 
project.  Subjects provided blood for monocyte isolation, quantification of serum 
Vitamin D and hsCRP levels, and genomic analysis.  
  
Inclusion/Exclusion criteria 
Inclusion Patient or control is willing to participate in the study and has provided 
informed consent 
Patients or controls aged 16 or over 
Patients’ with Crohn’s disease diagnosed by conventional clinical, 
radiological and histological criteria.  The disease can be either active or 
inactive 
Controls: Patients with a diagnosis of Irritable bowel syndrome 
diagnosed by standard means, or normal volunteers with no GI disorder 
and no personal or family history of inflammatory bowel disease 
Exclusion Patients under 16 or unable to give informed consent. 
Patients receiving anti-tissue necrosis factor (anti-TNF) medications 
Patients receiving corticosteroids 
Patients on immunosuppressants 
Patients who are pregnant, breastfeeding or <3 months postpartum 
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12.2 Patient baseline characteristics 
 
Table 9: Comparison of baseline characteristics of patients and healthy controls 
recruited to monocyte derived macrophage study 
  
 
Healthy controls 
(N=10) 
Crohn’s disease 
(N=10) 
p value 
Male (%) 50% 20% 0.177 
Age (y) 51.7 ± 3.8 44.8 ± 5.2 0.297 
Smoker (%) 10% 30% 0.290 
Harvey Bradshaw Index n/a 5.0 ± 1.7 n/a 
Serum Vit D3 (nmol/L) 30.8 ± 4.7 26.0 ± 3.7 0.433 
hsCRP (mg/L) 2.2 ± 0.6 7.8 ± 2.0 0.03 
NOD2 homozygote w/t 90% 80% 0.556 
NOD2 heterozygote 10% 20% 0.556 
ATG16L1 homozygote w/t 40% 40% 0.999 
ATG16L1 heterozygote 60% 50% 0.677 
ATG16L1 homozygote variant 0% 10% 0.343 
IRGM homozygote w/t 80% 70% 0.628 
IRGM heterozygote 20% 30% 0.628 
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12.3  Complete patient characteristics 
 
Table 10: Detailed characteristics of patients and healthy controls recruited to monocyte derived macrophage study 
 Sex Age Current 
smoker 
Montreal Harvey 
Bradshaw 
Index 
Vitamin 
D3 
(nM) 
hsCRP 
(mg/L) 
No. of altered 
alleles NOD2 
(rs2066844) 
No. of altered 
alleles NOD2 
(rs2066845) 
No. of altered 
alleles NOD2 
(rs2066847) 
No. of altered 
alleles 
ATG16L 
(rs2241880) 
No. of 
altered 
alleles IRGM 
(rs13361189) 
Fold change in 
intra-
macrophage 
HM605 
Fold change 
in intra-
macrophage 
K12 
Fold change 
in intra-
macrophage 
Staph 
Relative 
MDM induced 
Neutrophil 
chemotaxis  
HC 1 M 36 No n/a n/a 45 0.4 0 0 0 1 0 1.56 1.80 0.58 n/d 
HC 2 F 59 Yes n/a n/a 20 3.07 0 0 0 1 0 1.39 1.75 0.55 2.95 
HC 3 F 56 No n/a n/a 42 5.66 0 0 0 0 1 0.39 0.31 0.54 2.34 
HC 4 M 51 No n/a n/a 46 0.57 0 0 0 0 0 3.00 0.41 0.61 2.49 
HC 5 M 74 No n/a n/a 22 2.65 0 0 0 0 0 2.00 0.18 0.26 2.46 
HC 6 F 34 No n/a n/a 10 0.35 0 0 0 1 0 1.00 0.65 0.54 2.70 
HC 7 M 57 No n/a n/a 41 4.62 0 0 0 1 0 1.00 1.04 0.55 3.07 
HC 8 F 43 No n/a n/a 29 3.37 0 0 0 1 0 1.56 1.24 0.41 2.56 
HC 9 M 59 No n/a n/a 8 1.12 0 0 0 0 0 1.57 0.58 0.25 n/d 
HC 10 F 48 No n/a n/a 45 0.63 1 0 0 1 1 n/d 0.65 0.49 n/d 
                 
CD 1 F 38 No A2, L1, B3p 0 31 2.75 1 0 0 0 0 0.00 0.00 0.04 3.00 
CD 2 F 64 Yes A3, L1, B2 5 12 14.15 0 0 1 1 0 1.42 0.11 0.42 3.19 
CD 3 F 45 No A2, L1, B2 0 23 1.46 0 0 0 1 1 0.15 0.37 0.18 2.43 
CD 4 F 21 No A1, L3, B1 2 13 1.04 0 0 0 0 1 1.28 1.22 1.09 2.31 
CD 5 F 48 No A2, L1, B2 7 43 18.3 0 0 0 2 0 3.43 0.84 0.38 2.24 
CD 6 M 39 No A2, L1, B2 10 16 10.14 0 0 0 0 0 2.40 1.12 0.61 1.94 
CD 7 F 73 No A3, L2, B1 9 38 14.91 0 0 0 0 0 0.23 0.17 0.17 2.27 
CD 8 M 24 No A1, L1, B3p 1 36 3.95 0 0 0 1 1 0.38 0.18 0.20 2.87 
CD 9 F 40 Yes A2, L1, B2 16 33 4.84 0 0 0 1 0 1.20 1.16 0.31 2.80 
CD10 F 56 Yes A2, L3, B2p 0 15 6.95 0 0 0 1 0 0.36 0.27 0.25 2.48 
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13 Appendix 2 
 
13.1 Funding applications 
 
Initial funding for this research project was provided by the Liverpool National 
Institute for Health Research Biomedical Research Centre.  This funding stream 
finished at the end of March 2012.  Consequently I spent a significant part of my 
early research time applying for additional funding to allow completion of the 
project.  The applications and outcomes are summarised below.  No applications 
other than those listed below were submitted. 
  
Awarding body Award applied for Date submitted Outcome 
NIHR Biomedical 
research 
fellowship 
October 2011 Successful 
£12,000 consumables 
£2,819 training fund 
Crohn’s and Colitis 
UK 
Medical Research 
Award 
November 2011 Withdrawn following 
successful outcome 
of NIHR application 
Shire Shire Innovation 
Fund for SpRs 
January 2012 Successful 
£3,200 additional 
consumables 
 
  
195 
 
13.2 Output related to MD to May 2017 
13.2.1 Funding 
 NIHR Biomedical Research Fellowship – April 2012 to April 2013 
 Shire Development fund for SpRs, project grant - £3200 
 
13.2.2 Prizes and awards 
 British Society of Gastroenterology best poster award (IBD)  2014 
 ECCO IBD Advanced course (1 of 3 selected UK participants)  2013 
 Mersey Gastroenterology Group Research Prize    2012 
 CORE Belmont Trust Travel Award     2011 
 BSG Supraregional meeting travel bursary    2011 
 NIHR Biomedical Research Centre Scientific Training Fund  2011 
 
13.2.3 Papers 
 Flanagan PK, Chiewchengchol D, Wright HL et al.  Killing of Escherichia coli by 
Crohn's Disease Monocyte-derived Macrophages and Its Enhancement by 
Hydroxychloroquine and Vitamin D. Inflamm Bowel Dis, 2015 Jul;21(7):1499-
510 
 Tawfik A, Flanagan PK, Campbell BJ.  Escherichia coli-host macrophage 
interactions in the pathogenesis of inflammatory bowel disease.  World J 
Gastroenterol, 2014; 20(27): 8751-63 
 Prorok-Hamon M, Friswell MK, Alswied A, Roberts CL, Song F, Flanagan PK et al.  
Colonic mucosa-associated Diffusely-Adherent afaC+ Escherichia coli expressing 
lpfA and pks are increased in inflammatory bowel disease and colon cancer.  
Gut, 2014; 63(5):761-70 
 Flanagan PK, Campbell BJ, Rhodes JM.  Lessons from diversion studies and 
antibacterial interventions.  Digestive Diseases, 2012; 30 (4): 347-50 
 Flanagan P, Campbell BJ, Rhodes JM.  Bacteria in the pathogenesis of 
inflammatory  bowel disease.  Biochem Soc Trans 2011; 39 (4): 1067-72 
 Flanagan P, Campbell BJ, Rhodes JM.  Bacteria, good and bad - Host-microbiota 
interactions in inflammatory bowel disease.  The Biochemist 2011; 33 (4): 22-25 
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13.2.4 Book Chapters 
 Flanagan PK, Subramanian S.  Crohn’s disease.  Recent advances in 
Gastroenterology 12.  JP Medical Publishers, 2014, Ch2; 11-23 
 Flanagan PK, Rhodes JM.  Correction of microbiota disturbances or antagonism 
against specific pathogens in IBD.  Intestinal microbiota in health and disease.  
CRC Press, 2014; 230-51.   
 
13.2.5 Abstracts – Oral presentations 
 Flanagan PK, Campbell BJ, Rhodes JM.  Hydroxychloroquine as a treatment for 
Crohn’s disease: Enhancing antibiotic efficacy and macrophage killing of E. coli.  
DDF, 2012, OC-139 
 Flanagan PK, Campbell BJ, Rhodes JM.  Hydroxychloroquine inhibits intra-
macrophage replication of Crohn’s E. coli –BSG Supraregional Meeting, Sept 
2011 
 
13.2.6 Abstracts - Posters 
 Flanagan PK, Campbell BJ, Subramanian S, Rhodes JM.  Crohn’s disease 
monocyte-derived macrophages exhibit equivalent responses to 
intramacrophage bacterial infection relative to healthy controls.  BSG, 2014, 
PWE-091 
 Flanagan PK, Campbell BJ, Subramanian S, Rhodes JM.  Intracellular killing of 
bacteria is not impaired in Crohn’s disease monocyte-derived macrophages.  
UEGW, 2013, P1391 
 Flanagan PK, Campbell BJ, Rhodes JM.  Vitamin D enhances macrophage 
function and improves killing of Crohn's associated E. coli.  Ecco, 2013, P026 
 Flanagan PK, Campbell BJ, Rhodes JM.  Hydroxychloroquine Inhibits Intra-
Macrophage Replication of Crohn’s Disease E. coli and Enhances the 
Antimicrobial Effect of Antibiotics Doxycycline and Ciprofloxacin.  UEGW, 2011, 
P0513 
 
13.2.7 Additional Oral Presentations to Learned Societies 
 ASNEMGE Young Investigators Programme 2011 – Oral presentation and 
selected participant 
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13.2.8 Peer review 
 Invited reviewer for Tropical doctor – IBD clinical paper, 2012 
13.3 Protocol for antibiotic trial 
The trial protocol has not been included here due to space limitations. 
The trial is registered with ClinicalTrials.gov, is visible online and can be found using 
the identifier NCT01783106. 
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Figure 14-1.  Relative intramacrophage replication of E. coli HM605 (A), E. coli K12 
(B) and Staph aureus Oxford strain (C) in MDMs from patients with Crohn’s disease 
by disease location (ileal n=7, colonic n=1, ileocolonic n=2).  Active disease 
represented by open symbols, quiescent disease by solid symbols.  Statistical 
analysis was prevented by insufficient patients with isolated colonic disease. 
